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ABSTRACT 
 
The role of Neurofibromatosis Type 1 in Schwann Cell  
development and tumor formation and the influence of steroid hormones 
by 
Therese Mary Roth 
 
Chair: Kate F. Barald 
 
 The Neurofibromatosis Type 1 (NF1) gene functions as a tumor suppressor gene. 
One known NF1 function is to turn off the p21ras pathway by accelerating Ras 
hydrolyzation of active rasGTP to inactive rasGDP. Loss of neurofibromin (the protein 
product of the NF1 gene) in the autosomal dominant disorder NF1 is associated with 
tumors of the peripheral nervous system, particularly neurofibromas in which the major 
cell type is the Schwann Cell (SC).  We have developed an in vitro system for 
differentiating mouse embryonic stem cells (mESC) that are NF1 wild type (+/+), 
heterozygous (+/-), or null (-/-) into SC-like cells to study the role of NF1 in SC 
development and tumor formation. These SC-like cells, regardless of their NF1 status, 
express SC markers appropriate for their developmental stage, and support and 
preferentially direct neurite outgrowth from primary embryonic neurons. They are also 
capable of expressing myelin proteins.  NF1 null and heterozygous SC-like cells 
proliferate at an accelerated rate compared to NF1 wild type; this growth advantage can 
 
 
xv 
be reverted to wild type levels using a Mek inhibitor The mESC of all NF1 types can also 
be differentiated into neuron-like cells. The behavior and genetic repertoires of the cells 
under different developmental conditions can be compared, providing an ideal paradigm 
for studies of the role of NF1 in cell growth and differentiation of the different cell types 
affected by NF1.  
 The number and size of neurofibromas in NF1 patients has been shown to 
increase during pregnancy. SC-like differentiated mESC with varying levels of 
neurofibromin and NF1 tumor cell lines derived from a malignant and a benign human 
tumor, were used to study proliferation in response to hormones. Estrogen and androgen 
receptors showed very low/no expression in the NF1+/+ cells, low levels of expression in 
NF1+/- cells, and high levels of expression in NF1-/- cells. We have also found that an 
E2 metabolite, 2Methoxyestradiol, is cytotoxic to the NF1-/- malignant tumor cell line, 
and inhibits proliferation in the other cell lines. 2ME2 or its derivatives could provide 
new treatment avenues for NF1 hormone-sensitive tumors at times of greatest hormonal 
influence.  
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CHAPTER I 
 
INTRODUCTION 
 
HORMONE INVOLVEMENT IN NEUROFIBROMATOSIS TYPE 1 
 
NEUROFIBROMATOSIS TYPE I (NF1) - ORIGIN OF NEUROFIBROMAS 
 
 The tumor suppressor gene NF1, which encodes the neurofibromin protein, is 
responsible for one of the most common autosomal dominant disorders, in which all cells 
of the affected individual are heterozygous for the NF1 gene. This disorder, also called 
Neurofibromatosis type 1 (NF1), affects 1/3000 to 1/3500 individuals worldwide and 
occurs in equal frequency in males and females and across all ethnic groups (Friedman et 
al., 1999).  NF1 is a progressive disorder that may be quiescent for long periods, and is 
100% penetrant but demonstrates a wide range of severity that cannot be predicted even 
in family members who presumably carry the same mutation (Friedman et al., 1999).  
The human NF1 gene, located on chromosome 17q11.2, is extremely large, 335 kb with 
60 exons (figure 1.1). It is highly mutated even accounting for its large size; while 50% 
of NF1 patients inherit the mutant allele from a parent, 50% of the mutations are new, 
there are no “mutational hotspots” (Friedman et al., 1999).  NF1 encodes a more than 13 
kb transcript, which translates into the 250 kDa neurofibromin protein. Expression of 
neurofibromin is ubiquitous, however, expression is highest in the nervous system 
(Friedman et al., 1999). Neurofibromin expression is associated with microtubules, from 
 
 
2 
which it disaggregates on exposure to anti-mitotic drugs, such as colcemid (Gregory et 
al., 1993). Following colcemid removal, cells recovered microtubule assembly and NF1 
microtubule localization (Gregory et al., 1993). Mutations in NF1 are responsible for 
widely varying phenotypes, most but not all affected tissues are from neural crest-derived 
cells (figure 1.2), including numerous benign tumors of the peripheral nervous system 
such as cutaneous neurofibromas, plexiform neurofibromas and optic gliomas (for 
reviews, see Viskochil et al., 1993; Gutmann et al., 1994; Blum and Kambich, 1997; 
Feldkamp et al., 1998; Packer et al., 2002; Zhu et al., 2002). NF1 is also known as von 
Recklinghausen’s Disease: Fredrich Daniel van Recklinghausen was the first to describe 
the nervous tissue origin of the tumors in 1882 (Blickstein et al., 1988; Reynolds et al., 
2003). Neurofibromas are the most commonly found and potentially debilitating 
manifestations of NF1.  These benign growths, comprised mostly of Schwann cells (SC) 
or SC-like cells, but with substantive numbers of fibroblasts, mast cells, perineurial cells 
and vascular endothelial cells, arise on nerves that range in size from extremely small 
terminal branches to the spinal nerve roots. Mast cells are also found in other tumors, 
such as pancreatic β–cell tumors, mammary carcinomas, and squamous carcinomas 
(Roche, 1985; Soucek et al., 2007; Theoharides and Conti, 2007). Mast cells are required 
for tumor angiogenesis in mice, they secrete vascular endothelial growth factor (VEGF) 
and other cytokines necessary for angiogenesis (Roche, 1985; Soucek et al., 2007; 
Theoharides and Conti, 2007). NF1 has been reported to modulate mast cell growth 
(Ingram et al., 2001). NF1 patients cite such discrete neurofibromas as the single most 
significant burden of their disorder because of their disfiguring effects and associated 
physical and social discomfort (Wolkenstein et al., 2001; Page et al., 2006).  Discrete 
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neurofibromas may cause job loss, discrimination, low self-esteem, and social and 
psychological consequences that can require psychiatric intervention (Wolkenstein et al., 
2001; Page et al., 2006).  Although most discrete neurofibromas are cutaneous, arising in 
the dermis or epidermis, subcutaneous discrete neurofibromas have also been reported.  
Discrete tumors are rarely present at birth, but are found in 48% of 10 yr olds (notably, 
precocious puberty is a common feature of NF1) (Virdis et al., 2003), 84% of 20 year 
olds, and virtually all NF1 patients over the age of 40.  Hundreds and even thousands of 
these variably sized lesions have been found in adults with NF1.  Karvonen et al. (2000) 
reported that many tiny neurofibromas have been found in the normal-looking skin of 
NF1 patients, indicating a more widespread occurrence than was previously understood. 
Many have speculated that the number and size of these neurofibromas may increase in 
response to hormonal stimuli as commonly described by women during pregnancy, but a 
direct correlation of neurofibroma growth and hormonal stimulation remains to be 
elucidated. Large neurofibromas can also arise from multiple nerves within plexuses. 
These are termed plexiform neurofibromas (Packer et al., 2002). Diffuse plexiform 
neurofibromas are frequently associated with significant morbidity and even mortality. 
There are histopathological dissimilarities between discrete and diffuse plexiform 
neurofibromas, suggesting that different mechanisms may exist for the formation of these 
different types of neurofibromas (Palmer et al., 2004). Plexiform neurofibromas, first 
arising in early childhood, are often relatively stable for a number of years but are 
capable of aggressive growth, particularly as puberty approaches or during pregnancy. 
Nodular plexiform neurofibromas can also cause serious neurological dysfunction. About 
5% of plexiform neurofibromas undergo malignant transformation and eventually 
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become malignant peripheral nerve sheath tumors (MPNSTs) (Woodruff, 1999). A 
hormonal “trigger” may be responsible both for growth of the tumors and for such 
malignant transformation (Posma et al., 2003) but a direct causal relationship has not 
been firmly established.  The physical and emotional burden of NF1 is therefore 
enormous (Wolkenstein et al., 2001; Sebold et al., 2004; Graf et al., 2006; Page et al., 
2006). 
 
NF1 IS A TUMOR SUPPRESSOR GENE; ROLE OF LOSS OF 
HETEROZYGOSITY 
  NF1 patients inherit only one functional allele (and are therefore genetically 
heterozygous for NF1), and the second allele is lost in most, but not all, cells in the 
tumors. This “second hit” results from loss of heterozygosity (LOH) in specific cells 
(figure 1.3), but it is not clear what role LOH actually plays in tumorigenesis, although it 
is thought to be essential. The lack of a functional gene product, the protein 
neurofibromin, is thought to cause the aberrant cellular proliferation characteristic of 
neurofibromatosis type 1 (Packer et al., 2002).   However, loss of heterozygosity (LOH) 
has been found in some, but not all neurofibromas, and in some but not all cell types 
within the neurofibromas themselves (Zhu et al., 2002).  Zhu and Parada (Zhu et al., 
2002; Parada et al., 2005) hypothesized that LOH occurs in neural crest stem cells early 
in embryogenesis (figure 1.3).  These stem cells then differentiate to form both Schwann 
cells (SC) and peripheral nervous system (PNS) nerve cells.  Nerve cells induce 
proliferation of the NF1
-/-
 SC, which then recruit both heterozygous fibroblasts and SCs.  
Therefore, SCs are probably the primary cells involved in the formation of 
neurofibromas, although the presence of two SC types, one with and one without LOH, 
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suggests that LOH may be the primary event triggering neurofibroma formation, but may 
not be the sole event (Fishbein et al., 2005). A major unanswered question is whether a 
decrease in neurofibromin as a result of haploinsufficiency can be sufficient to induce 
neurofibroma formation, or whether other mutations, at the NF1 locus or other loci (e.g. 
P53, retinoblastoma), or environmental conditions including trauma, altered blood supply 
and possibly the elevated levels of specific hormones, seen at puberty and during 
pregnancy, could also serve as necessary triggers (Horyn et al., 1988; Zhu et al., 2002; 
Parada et al., 2005). 
 
PROLIFERATION VS. DIFFERENTIATION; THE ROLE OF NF1’S RAS-GAP 
FUNCTION 
  Cell differentiation is known to be important in suppression of both tumor growth 
and malignancy.  Neurofibromin may suppress aberrant cellular proliferation by 
promoting cell differentiation, possibly through its interaction with Ras. Neurofibromin 
contains a domain homologous to the ras GTPase-activating protein, GAP (Weiss et al., 
1999).  NF1 can be considered a gene regulating programmed cell death, because one of 
neurofibromin’s functions is to serve as a ras-GAP, which accelerates the conversion of 
active Ras-GTP to inactive Ras-GDP (figure 1.4).  The ras-GAP region of the NF1 gene 
responsible for its tumor suppressor function is located at exons 21-27a, labeled the Ras-
GRD (GAP-related domain) (figure 1.1). NF1’s Ras-GTP suppression activity inhibits 
cell growth and promotes apoptosis.  Mutations that inactivate NF1 reduce the 
suppressive activity of Ras-GTP and promote cellular proliferation. Ras-GTP levels are 
elevated in plexiform neurofibromas (Feldkamp et al., 1999), which could explain the 
pronounced hyperplasia seen in these tumors. Ras-GTP levels were found to be normal in 
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fibroblasts from four individual neurofibromas and a plexiform neurofibroma (Sherman 
et al., 2000).  However, in the same tumors, Schwann cells were heterogeneous in their 
expression of Ras-GTP.  The activity of p21ras is also known to be involved in many 
types of cell differentiation (Cichowski and Jacks, 2001; Packer et al., 2002) including in 
vitro neuronal differentiation.  In neurons under normal conditions, it may also play a role 
in various neurotrophin-mediated neuronal differentiation and survival mechanisms 
(Klesse and Parada, 1998; Klesse et al., 1999), probably through interaction with 
phosphatidylinositol 3' kinase (PI3K) (Klesse and Parada, 1998; Klesse et al., 1999). The 
mTOR (target of rapamycin) pathway has also been implicated in NF1 (Dasgupta et al., 
2005; Johannessen et al., 2005).  
 NF1’s roles in proliferation, differentiation and apoptosis are context-dependent. 
Loss of NF1 expression could therefore result in either loss of proliferation or increased 
proliferation.  
  
CELLULAR MECHANISMS; NF1’S ROLE AS A REGULATOR OF FINAL 
NEURONAL NUMBERS IN THE PERIPHERAL NERVOUS SYSTEM 
 The Neurofibromatosis 1 (NF1) gene and its protein product, neurofibromin, have 
been demonstrated to have important roles in regulating the normally occurring 
programmed cell death (apoptosis) that is vital to the correct formation of the nervous 
system and other developmental systems in the embryo (Li and White, 1996; Klesse and 
Parada, 1998; Lakkis and Epstein, 1998; Roth et al, 2007a).  Apoptosis is a normal 
physiological process that regulates cell populations in both the developing embryo and 
the adult (Wyllie et al., 1980).  It is particularly important in regulating the final cell 
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numbers of neurons and glial cells in the nervous system, because about twice as many 
cells are produced as are needed for the final functional system (reviewed by 
Heidenreich, 2003). NF1 is hypothesized to be, by an as yet unknown mechanism but 
possibly through attenuated Ras signaling, responsible for promoting cell death of normal 
excess neurons and glial (Schwann) cells during development.  In the absence of this 
tumor suppressor gene, cell types that are not postmitotic (as neurons are) can proliferate 
uncontrollably, producing both the plexiform and cutaneous benign neurofibroma tumors 
characteristic of the disorder (Feldkamp et al., 1998).  
 
NEUROFIBROMATOSIS TYPE 1 (NF1) IN A CHANGING HORMONAL 
MILIEU: NF1 AND PREGNANCY 
 The incidence of pregnancy among NF1 patients is relatively low and is inversely 
correlated with the severity of the disease (from about 1/5000 to about 1/18,000 
obstetrical patients has NF1, compared with 1/3000-1/3500 in the general population) 
(Blickstein et al., 1988; Weissman et al., 1993). Blum and Kambich (1997) stress that 
obstetrical complications are important considerations for NF1-affected women of 
childbearing age, particularly in certain societies and third-world countries. They 
speculate that women with very mild cases of NF1 are frequently not diagnosed and their 
disorder either does not complicate pregnancy or, if symptoms worsen during the 
pregnancy, NF1 is then diagnosed.  They further comment that women with severe 
clinical manifestations of NF1 rarely elect to bear children except in underdeveloped 
countries.  There has been a reported increase in the number and size of cutaneous and 
plexiform neurofibromas with pregnancy going back over 100 years (Brickner, 1906; 
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Dugoff and Sujansky, 1996; Isikoglu et al., 2002; Posma et al., 2003); reviewed in (Blum 
and Kambich, 1997). There have been reports that pregnant NF1 patients with giant 
“royal” tumors are more affected than patients with only nodular tumors, with possible 
reciprocal effects between NF1 and pregnancy (Blickstein et al., 1988). The earliest 
obstetrical description of NF1, termed “fibroma molluscum gravidarum” was in 1906, by 
Brickner, while the adverse associations between NF1 and pregnancy were first 
recognized by Hirst in 1911 (Brickner, 1906; Blickstein et al., 1988). 
 Only two studies of NF1 patients during pregnancy involved relatively large 
numbers of patients (Weissman et al., 1993; Dugoff and Sujansky, 1996).  The Dugoff 
and Sujansky study reported on 105 women and 180 pregnancies: 60% of patients 
reported growth of new neurofibromas; 52% experienced enlargement of existing 
neurofibromas, sometimes with a decrease in size of nodules after delivery (Dugoff and 
Sujansky, 1996).  However, multiparous women who had NF1 experienced new growth 
of neurofibromas only in some pregnancies (Dugoff and Sujansky, 1996), even though 
hormone levels should be similar for each. Growth of Schwannomas as well as 
neurofibromas was also reported in NF1 patients during pregnancy (Swapp and Main, 
1973; Ribella, 1975). Obstetric complications are important considerations for affected 
women of childbearing age (Blum and Kambich, 1997).  This is possibly due to mild 
cases remaining undiagnosed or severe cases more subject to report, as well as low 
marriage rates due to cosmetic disfigurement or voluntarily choosing to remain childless 
(Blickstein et al., 1988; Blum and Kambich, 1997).    
 Malignant degeneration of neurofibromas during pregnancy has also been 
reported (Ginsburg et al., 1981; Baker et al., 1989; Puls and Chandler, 1991; Posma et al., 
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2003), as well as maternal death from an intracranial hemorrhage resulting from a 
glioblastoma that recurred during pregnancy (Hadi, 1995).  A second pregnancy resulted 
in the overgrowth of a peripheral nerve sheath tumor that had initially arisen during a first 
pregnancy, which proved fatal to the patient (Posma et al., 2003).   Another case report 
found that a patient with initially mild disease symptoms died of the results of multiple 
malignancies, which the physician believed arose and became worse during and after 
pregnancy and delivery (Heffner, 1969). Boiten et al. (1987) also reported a combination 
of central nervous system tumor enlargement, new tumor appearance, hydrocephalus and 
hypertension in a pregnant patient with NF1. 
 Weissman et al. (1993) also reported a higher than expected rate of first trimester 
spontaneous abortions (20.7%), still births (8.7%) and intrauterine growth retardation 
(13.0%), which were not seen or possibly not reported in the Colorado study (Dugoff and 
Sujansky, 1996).  Additional studies have also reported growth retardation of the fetus in 
patients with NF1 (Belton et al., 1984; Blickstein and Lancet, 1987). An excellent review 
of all of these aspects can be found in Blum and Kambich (1997). 
In patients with NF1, pregnancy can cause severe hypertension and/or blood 
vessel weakness. An increased risk of hypertension has been recognized in all adults with 
NF1, but severe hypertension has been specifically noted in pregnant patients with NF1 
(Wiznitzer et al., 1986; Bertrand et al., 1992; Hagymasy et al., 1998) including some 
earlier studies of patients whose pregnancies had to be terminated because of life-
threatening conditions (Edwards et al., 1983). The most common causes of hypertension 
in NF1 patients are renal artery stenosis or phaeochromocytoma, but possible 
mechanisms have not been reported (Humble, 1967; Criado et al., 2002). At least one 
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case was found in which the undiagnosed NF1 led to fatal complications under anesthesia 
(Humble, 1967).  There have also been reports in the literature of blood vessel rupture 
during pregnancy in NF1 patients, including a report of a patient with fatal renal artery 
rupture (Tapp and Hickling, 1969) and another NF1 patient whose arm was amputated 
after brachial artery rupture (Tidwell and Copas, 1998). However, at least one report 
(Jarvis and Crompton, 1978) of a study of hypertension in ten pregnant patients with NF1 
in the course of twenty-seven pregnancies found only two cases of pre-eclampsia, a still 
birth and four spontaneous abortions. The majority of pregnancies in this study 
demonstrated no evidence of hypertension; the number of hypertensive NF1 patients was 
also reportedly low in another study (Weissman et al., 1993), and no excessive 
hypertension was reported in the (Dugoff and Sujansky, 1996) study.  No record was 
made of the patients’ lesions, however, or whether they were affected by the pregnancies. 
Another study that attempted to relate hypertension to the number of neurofibromas 
found that development of hypertension and poor outcome in NF1 pregnancies is directly 
proportional to the number of lesions found in the patient (Sharma et al., 1991).  
 Prospective studies, such as those cited above, involved patients with relatively 
mild forms of the disorder whose pregnancies were obstetrically uneventful even if there 
are reported increases in size and number of their neurofibromas (Dugoff and Sujansky, 
1996).  In contrast, a large number of retrospective case studies by obstetricians and 
gynecologists tend to involve only a few women (Ansari and Nagamani, 1976) or even 
single patients, (Ribella, 1975) and report severe and therefore particularly notable 
effects.  
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Essentially all of these studies, both large and small, are descriptive, providing no 
significant insight to the pathogenesis of disease progression or mechanisms of 
complications such as the severe hypertension seen in some NF1 patients. None of these 
reports presents a functional study of the mechanism of new lesion growth or the 
enlargement of preexisting lesions during pregnancy. One study done on both male and 
female neurofibroma tumors found 75% expressed progesterone receptor (PR), while 5% 
expressed estrogen receptor (ER ) (McLaughlin and Jacks, 2003). Both male and female 
tumor cells were tested, and, whether these tumors came from men or women was not 
significant with regard to PR and ER expression (McLaughlin, personal communication). 
A recent paper has been published that investigates the potential role of steroid hormone 
action on the growth, proliferation and tumorigenicity of cells that do or do not express 
the NF1 gene or its protein product, neurofibromin. It is the first published study of RNA 
levels of steroid hormone receptors in primary NF1 tumor cells, Schwann Cell (SC)-
enriched NF1 tumor cells and normal SC, along with an analysis of proliferation and 
apoptosis. This study found a great deal of heterogeneity among the cell types, regardless 
of tumor origin or gender, suggesting the importance of each individual tumor’s 
microenvironment (Fishbein et al., 2007).  
 
THE HORMONAL MILIEU DURING PREGNANCY 
 Concentrations of the steroid hormones 17-estradiol (E2), progesterone (P4) and 
testosterone (T) are upregulated during pregnancy (Witorsch, 2002; Fernandez-Valdivia 
et al., 2005; Okada et al., 2005; Rodriguez-Cuenca et al., 2006). Steroid hormones are 
synthesized from cholesterol, with P4 synthesized first, followed by T, which is a 
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precursor for E2, which is converted to E2 through the aromatase enzyme in the ovary 
(Gao et al., 2005) (figure 1.5) . E2 has been shown to be involved in cell proliferation, 
and is a ligand for the estrogen receptor (ER) (Revankar et al., 2005; 
Boonyaratanakornkit and Edwards, 2007). P4 is modified to E2 and is involved in both 
proliferation and differentiation (Fernandez-Valdivia et al., 2005); P4 is the ligand for the 
progesterone receptor (PR) (Fernandez-Valdivia et al., 2005; Boonyaratanakornkit and 
Edwards, 2007). The E2 regulates PR by transactivation through the ER (Fernandez-
Valdivia et al., 2005; Okada et al., 2005). Steroids can, although rarely, cross-react and 
bind to receptors other than their native receptor, because of the similarity of their 
receptor conformation, even though the actual sequence identity may be low (Gao et al., 
2005) (figure 1.6). Testosterone is the primary circulating androgen, even in women, and 
is the ligand for the androgen receptor (AR), although it can also cross-react with both the 
ER and PR, albeit with very low affinity (Gao et al., 2005; Boonyaratanakornkit and 
Edwards, 2007). Steroid receptors (ER, PR, and AR) belong to the nuclear receptor 
family of transcription factors, which are activated when their ligand (E2, P4 or T) binds 
to the cytoplasmic-envelope-anchored receptor and the complex subsequently enters the 
nucleus to bind to hormone response elements (HRE) in gene promoter regions, thereby 
activating transcription of downstream effector genes (Fernandez-Valdivia et al., 2005; 
Boonyaratanakornkit and Edwards, 2007; Gavrilova-Jordan and Price, 2007) (figure1.7). 
Breast cancer tumor cells which express both ER and PR have a better prognosis because 
they are more likely to respond to hormone antagonist treatment (Jacobsen et al., 2003), 
although tumors that express only ER or PR, but not both, have been reported to have a 
poorer outcome (Jacobsen et al., 2005).  
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Steroid hormone action is not mediated exclusively through classical pathways 
(McEwen and Alves, 1999; Ho and Liao, 2002; Zhang et al., 2004; Chen et al., 2005; 
Gao et al., 2005; Jacobsen et al., 2005; Revankar et al., 2005; Sonneveld et al., 2006; 
Gavrilova-Jordan and Price, 2007). There have been reports of steroid hormones (P4, E2, 
T) influencing cells independent of their classical receptors (PR, ER, AR) (McEwen and 
Alves, 1999; Ho and Liao, 2002; Zhang et al., 2004; Chen et al., 2005; Gao et al., 2005; 
Jacobsen et al., 2005; Revankar et al., 2005; Sonneveld et al., 2006; Gavrilova-Jordan 
and Price, 2007). Conversely, the receptors have also been shown to exert their influence 
without hormones (Chen et al., 2005; Jacobsen et al., 2005; Sonneveld et al., 2006). ER 
expression has been seen outside the nucleus (McEwen and Alves, 1999; Ho and Liao, 
2002; Zhang et al., 2004; Revankar et al., 2005). E2 has also been shown to modulate 
secondary messengers, such as Ca++ and NO, and activate the PI3K/Akt and MAPK 
pathways (Ho and Liao, 2002; Boonyaratanakornkit and Edwards, 2007; Gavrilova-
Jordan and Price, 2007). These effects are not inhibited by ER inhibitors, suggesting they 
are not mediated through the classical receptors (Ho and Liao, 2002) (figure 1.6). 
We put forward the hypothesis that hormones, particularly those that rise during 
puberty and pregnancy, are responsible for the observed increase in both size and 
numbers of cutaneous and plexiform neurofibromas in both adolescent and pregnant 
patients with NF1. It has also been postulated that hormones are also involved in the 
progression of benign lesions (neurofibromas) to MPNST (Fishbein et al. 2007). A recent 
study describes RNA levels of steroid hormone receptors, along with the effects of the 
steroid hormones progesterone (P4), estrogen (E2), or testosterone (T) on primary and 
SC-enriched human benign and malignant NF tumor cell lines and normal SC (Fishbein 
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et al., 2007). Fishbein et al. found a great deal of heterogeneity in estrogen receptor, 
progesterone receptor, and androgen receptor expression in normal SC and most NF1 
tumor samples tested, with no clear division based on tumor type or gender (Fishbein et 
al., 2007). The greatest variation in hormone receptor levels occurred between primary 
tumor cells versus SC-enriched tumor cell cultures, suggesting that other cell types other 
than the SC have steroid hormone receptors.  There were also some statistically 
significant differences in proliferation and apoptosis in cells exposed to steroid hormones 
or their antagonists, but these differences were also heterogeneous.  The data reported did 
not fit into a simplistic or global model to explain the functional role of hormonal 
pathways in the progression of NF1. The data did suggest that the surrounding cells 
unique to each tumor’s microenvironment were important to tumorigenicity, and that 
classical steroid receptor effects may only apply to a subset of NF1 tumors, regardless of 
gender (Fishbein et al., 2007). There is also work in progress from our laboratory 
studying Schwann Cell-like (SC-like) differentiated mouse embryonic stem cells that 
have been engineered to lack neurofibromin (Roth et al., 2007a; Roth et al., 2007b).  
The most potent hormone effector in pregnancy is estrogen in the form of 
17βestradiol (E2).  It promotes the proliferation of endometrial cells in the uterus, and is 
essential for maintaining pregnancy.  It is initially produced by the corpus luteum and 
later by the placenta.  Additional estradiol species are also produced, including 
17αestradiol (also called 17αE2), which is a weak estrogen that induces some estrogen 
responsive genes, including vascular endothelial growth factor (VEGF), which promotes 
angiogenesis--new blood vessel formation.  However, its action in rat pituitary tumor 
cells is independent of the estrogen receptors (ER), but acts through the PI3Kinase-AKT 
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signaling pathway.  There is also evidence that this is the pathway through which the NF1 
protein product, neurofibromin, acts (Klesse and Parada, 1998).    
E2 also has proliferative effects on estrogen-responsive tumor cells.  A report by 
Ahmad et al., (1999) demonstrated that in the MCF-7 breast carcinoma cell line, E2 
upregulates AKT activity and increases cell proliferation.  Both ICI 182, 780 (ICI), a pure 
antiestrogen and wortmannin (a PI3K inhibitor) block this effect (Ahmad et al., 1999).  In 
addition, Wilson et al., (2002) have demonstrated that estradiol treatment reduced the 
number of neuronal cells undergoing apoptotic cell death. They examined the level of 
activation of Akt kinase that mediates the antiapoptotic signals.  Explants treated with 
estradiol had elevated levels of pAkt and treatment with ICI prevented the effect of 
estradiol, suggesting that estradiol prevents injury-induced apoptosis in neurons and that 
Akt activation is probably responsible for this effect (Wilson et al., 2002).  Although the 
evidence at this time is only circumstantial, there is a good possibility that the two 
pathways, the NF1-dependent pathway and the estrogen-dependent pathway, both 
interact through effects on PI3 Kinase.  
Progesterone (P4) is also critical for maintaining pregnancy.  P4 can be involved 
in cell differentiation and modulation of E2 proliferative effects. E2 and P4 can have 
complementary functions, with P4 inhibiting the ER (Jacobsen et al., 2003). P4 and E2 
can be used in combination to stimulate tumor development by simulating pregnancy in 
mice with dormant mammary tumors (Gattelli et al., 2004). The combination of E2 and 
P4 caused the tumor cells to break dormancy and begin proliferating. The classical 
progesterone receptor (PR) inhibitor RU486 also has inhibitory effects on the 
glucocorticoid receptor (GR) (Ghoumari et al., 2003; Zhang et al., 2006). 
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There are two distinct forms of the estrogen receptor (ER), ERα and ERβ, which 
are transcribed from different genes (Boonyaratanakornkit and Edwards, 2007). Both 
subtypes bind estrogens as well as selective ER modifiers (SERMs) including the anti-
cancer agent tamoxifen and a number of other anti-cancer ER inhibitors (Cummings, 
2002; Boonyaratanakornkit and Edwards, 2007).  ER receptors are classically located in 
the nucleus although they can also be located in the nuclear or mitochondrial membrane 
(Gavrilova-Jordan and Price, 2007).  PRs and androgen receptors (AR), have also been 
found on mitochondrial membranes, and are very similar/identical to classical nuclear 
steroid receptors (Gavrilova-Jordan and Price, 2007). At high concentrations, E2 is also 
able to bind to the AR (Yeh et al., 1998). 
Classical steroid receptors form dimers, interact with basal transcription factors 
and coactivators and bind to hormone response elements in DNA, leading to the 
modulation of target gene transcription. The distribution of the ER and PR subtypes 
varies among tissues and among cells in a specific tissue, and their expression also varies 
during development (Van Den Bemd et al., 1999; Boonyaratanakornkit and Edwards, 
2007).  
ICI 182,780 (ICI) at 10
-7
 M is a pure antiestrogen that leads to the downregulation 
and subsequent loss of the estrogen receptors themselves (Wakeling et al., 1991; Van 
Den Bemd et al., 1999; Cicatiello et al., 2000).  It also has estrogen receptor antagonistic 
effects and inhibits estrogen binding to both the α and β forms of the human estrogen 
receptor (ER) (Robertson et al., 2001; Garnier et al., 2003).  ICI has been shown to 
inhibit the growth of breast cancer cells and cell lines (Robertson et al., 2001).  It has also 
been shown to be effective against tamoxifen-resistant breast cancer in post- menopausal 
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women (Robertson, 2001).  ICI induces a conformational change in the ER and induces a 
ligand concentration-dependent increase in its proteolytic degradation. (Hyder and 
Stancel, 2002) also showed that ICI has antiprogestin effects in a human breast cancer 
cell line, blocking progesterone responsive genes such as vascular endothelial growth 
factor (VEGF), which is a potent angiogenic growth factor.  ICI blocked progestin-
induced VEGF mRNA and protein synthesis (Hyder and Stancel, 2002), although it did 
not block binding of progestin to the PR or down-regulate the endogenous PR.  Estrogen 
does not upregulate VEGF in these breast cancer cells.  Therefore ICI could block 
angiogenesis in the breast cancer cell line through a mechanism unrelated to its ER 
inhibition and the authors suggest that either ICI binds to a site in the PR different from 
its ligand binding site and/or ICI binds to a co-activator or co-repressor or to yet another 
protein involved in the transcriptional complex associated with responsive genes such as 
VEGF.  ICI also effectively inhibits the ER in the hippocampus but not the frontal cortex 
of the brain (Mize et al., 2003).  Studies in both rodents and primates have shown that 
progestins can counteract the antiatherogenic effects of estrogens.  ICI inhibits these 
effects demonstrating that the antiatherogenic effects of E2 are mediated through ER and 
studies with ER knockout mice also demonstrate that ERs mediate these protective 
effects of estrogen on the vasculature (reviewed by Karas, 2002).   
2-Methoxyestradiol (2ME2) is a natural estrogen metabolite of E2 that has no 
estrogenic effects itself but has both antiangiogenic and antitumorigenic effects (Fotsis et 
al., 1994; Lin et al., 2001; Schumacher and Neuhaus, 2001; Carothers et al., 2002), 
including effects on osteosarcoma (Maran et al., 2002) and Ewing sarcoma (Djavaheri-
Mergny et al., 2003).  Both microvasculature and large vessel endothelial cell 
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proliferation are also blocked by 2ME2 (Fotsis et al., 1994).  Proliferation of many types 
of normal cells, including thyroid cells (Wang et al., 2000) and chondrocytes in the 
growth plate (Sibonga et al., 2002) are inhibited by 2ME2.  However, 2ME2-induced 
apoptosis is independent of the ER α and β (LaVallee et al., 2002). 2ME2 anti-angiogenic 
activity occurs through impaired hypoxia inducible factor-1 (HIF-1) accumulation, which 
results in inhibited vascular endothelial growth factor (VEGF) expression (Mabjeesh et 
al., 2003). Analogues of 2ME2 have been made and tested for their enhanced inhibitory 
abilities and one analogue, 14-Dehydro-2-ME-2, was 16-fold more potent than 2-ME2 
against various tumor cell lines, including prostate cancer cell lines (Tinley et al., 2003).  
An important study of 2ME2 published in 2001 by Brueggemeier et al. (2001) 
demonstrated that 2ME2, which has only weak affinity for the ER, not only has 
antiproliferative activity but also alters tubulin dynamics.  A variant of this metabolite, 2-
methoxymethylestradiol, was more effective than the native metabolite in producing 
cytotoxicity and altering tubulin dynamics in intact cells (Brueggemeier et al., 2001).   
During pregnancy, 2ME2 may put a growth check on estrogen-stimulated cell 
growth.  We hypothesize that (1) levels of both estrogens and 2ME2 may be different in 
women with NF1 from those in women without NF1 and (2) 2ME2 levels might be lower 
in NF1 patients. If 2ME2 levels are lower in individuals with NF1, 2ME2 may be unable 
to compensate for estrogen levels that promote the growth of neurofibromas and might 
also be involved in the conversion of benign to malignant tumors that has also been 
reported in some pregnant NF1 patients (Posma et al., 2003).  However, there are no 
studies in the literature examining the levels of hormones or hormone metabolites in 
pregnant women with NF1.   Almost all of the studies published to date about women 
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with NF1 are descriptive.  There are no studies of the mechanism by which any of these 
hormones or metabolites act on cells that do or do not make neurofibromin. Studies on 
the effects of 2ME2 derivatives on NF1 tumor cell growth can be found in the appendix 
at the end of this dissertation. 
 
NEUROGENERATIVE AND NEUROPROTECTIVE EFFECTS OF STEROID 
HORMONES 
 In a recent study (MacLusky et al., 2003), the neuroprotective effects of estradiol 
and progesterone were examined in a model of neuronal apoptosis induced by growth 
factor insufficiency. Estradiol and progesterone were able to maintain neuronal 
phenotypes in PC12 cells induced to become neuron-like by nerve growth factor (NGF), 
but not in naïve PC12 cells that were not NGF treated.  The E2 protective effect could be 
inhibited by ICI, indicating that the effect was probably mediated through the ER.  It was 
also dependent on RNA and protein synthesis (MacLusky et al., 2003).  It is thought that 
ERα is particularly important in mediating this effect.  (Ivanova et al., 2002) found that 
estrogens stimulated the differentiation of neuronal and neural networks in the central 
nervous system. E2 was found to increase the expression of glial cell-derived 
neurotrophic factor (GDNF) in developing hypothalamic cells in culture.  An additional 
report (Brannvall et al., 2003) demonstrated that both embryonic and adult rat neural 
stem cells (NSC) have both ERs and that E2 treatment decreased the proliferation of NSC 
stimulated by epidermal growth factor (EGF).  This was EGF receptor (EGFR) 
dependent, necessitating the examination of the mouse embryonic stem cells used in 
these studies for all three receptors (EGFR, and ER α and β).  This report further 
demonstrated that E2 increased the ratio of neurons to glial cells in embryonic NSC but 
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not in the adult NSC, suggesting that E2 influences neurogenesis only during embryonic 
development.  However, neuronal regeneration in areas of the brain known to regenerate 
neurons (e.g. olfactory bulb, hypothalamus) was not examined. Estrogen (E2) upregulates 
the retinoic acid receptor a (RARa) in human breast cancer cells at both the RNA and 
protein levels.  Two regions of the promoter sequence appear to be sensitive to the 
estrogen stimulation; however, ER DNA binding ability is not required for the estrogen-
induced increases in this transcriptional activity (Elgort et al., 1996).  Nerve growth 
factor levels were measured in the serum of NF1 patients before pregnancy, during the 
course of pregnancy and post-pregnancy.  There were no significant differences among 
the levels measured at any stage or between NF1 patients and control subjects who do not 
have NF1 (Elgort et al. 1996).   
 
POSSIBLE ROLE OF STEROIDS IN HYPERTENSION AND VASCULAR 
STRUCTURE ALTERATIONS SEEN IN PREGNANT PATIENTS WITH NF1 
 Vascular endothelial growth factor (VEGF) is a major inducer of tumor 
angiogenesis (Ruohola et al., 1999).  It is expressed in endothelial cells, and its 
expression in cancer cells, such as breast cancer cells indicates a poor prognosis for 
tumor progression. Neurofibromas tend to be highly vascular (Thomas and De Vries, 
2007). 17βestradiol (E2) upregulates VEGF mRNA in many cancer cells (Ruohola et al., 
1999), leading to subsequent angiogenesis. This E2-mediated angiogenesis could also be 
responsible for the growth of neurofibromas, which need vascularization to survive 
beyond microscopic sizes. This increased growth could also result in the appearance of 
new tumors during pregnancy, if previously microscopic tumors grow to detectable sizes. 
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ICI 182, 780 (ICI) inhibits the E2-mediated upregulation, indicating that it probably acts 
by an ER-dependent mechanism (Ruohola et al., 1999). In contrast, tamoxifen also 
upregulates VEGF mRNA on its own and has no inhibitory effect like that of ICI 
(Ruohola et al., 1999).  
E2 inhibits vascular smooth muscle cell proliferation whereas ICI causes 
proliferation of these cells (Lavigne et al., 1999). Teoh et al. (1999) reported that short-
term exposure to pharmacological levels of 17α or 17βestradiol (E2) produced relaxation 
in pig coronary artery in organ culture.  However, physiological concentrations of 
estradiol also enhanced the endothelium-independent relaxation of pig coronary artery 
produced by other agents.  This relaxation was not blocked either by tamoxifen or by ICI, 
suggesting that the effect is mediated through a different ER and that 17βestradiol may be 
responsible for acute affects on blood flow by a different mechanism than that involved 
in ER downregulation. Additional effects on vasculature include effects on the integrity 
of the endothelial cell lining of blood vessels that is affected by E2 (Cho et al., 1998). 
Tight junctions between the endothelial cells are critically important for maintaining the 
integrity of the blood vasculature. Estradiol increases the cation specificity of the tight 
junctions. In addition, E2 also acts as an antioxidant at the genomic level. By improving 
the NO/O2
-
 balance; E2 keeps the expression of proatherosclerotic gene products low and 
regulated in endothelial cells (Wagner et al., 2001).   
Extracellular Ca
++
 is essential for maintaining occlusion of the paracellular space 
in endothelial cells by tight junctions (Cho et al., 1998). If extracellular calcium is 
lowered, cells separate weakening blood vessel walls and leading to rupture (Cho et al., 
1998). Estrogen modulates tight junctional resistance across the endothelial cells (Teoh et 
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al., 1999). Estrogen increases the tight junctional permeability to ions (Teoh et al., 1999).  
A nuclear receptor, possibly other than ER, mediates the effect of estrogen on cation 
selectivity (Revankar et al., 2005).     
 
POSTULATED INTERACTIONS OF NF1, ESTROGENS AND 
APOPTOSIS PATHWAYS 
We hypothesize that hormones influence NF1-mediated apoptotic events through 
the phosphatidylinositol 3 Kinase (PI3K) pathway, which has been implicated in NF1 
signal transduction (Yao and Cooper, 1995; Klippel et al., 1996; Rodriguez-Viciana et 
al., 1996; Kulik et al., 1997; Parrizas and LeRoith, 1997; Stokoe et al., 1997; Crowder 
and Freeman, 1998; Klesse and Parada, 1998; Klesse et al., 1999).  A report also suggests 
that the PI3K cascade mediates the neuroprotective effects of estrogen on cortical 
neurons (Honda et al., 2000).  
 Over the past decade, the scientific community has gained significant insight into 
the genetic mechanisms underlying NFI.  However, to date the hormonal pathways 
modulating NF1 phenotypes have not been well elucidated.  Over the years, patients with 
NF1 have reported a dramatic change in tumor number and size during puberty as well as 
pregnancy, suggesting hormonal regulation of tumor growth (Ansari and Nagamani, 
1976; Blickstein and Lancet, 1987; Dugoff and Sujansky, 1996; Isikoglu et al., 2002).  
While this possibility has always been viewed as being quite plausible given our 
recognition of hormonal responsiveness in many tumor types, little scientific evidence 
has supported this clinical observation. Recently, new insights into the hormonal 
regulation of neurofibromas’ growth have been reported as summarized above.  We also 
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hypothesize that the effect of hormones on neurofibromas may be indirect through their 
effects on angiogenesis. Increased blood vessel formation during pregnancy could allow 
existing tumors to grow, as well as increase microscopic tumors to grow to detectable 
sizes. Further studies into the molecular mechanisms by which hormonal stimulation can 
regulate the growth of neurofibromas or blood supply is necessary to provide a more 
accurate understanding of the natural history of the disease, as well as for the 
development of innovative tools for the management of patients who have NF1.  
Recognition by clinicians of the hormonal impact of NF1 is essential to provide care of 
patients.  Ideally, further knowledge about the pathways and modifying facts of NF1 will 
be instrumental in improving the prognostic and therapeutic management of the disease 
as well. 
 
 
24 
 
 
 
Figure 1.1: NF1 structure. NF1 is a very large gene, spanning 350 kb and comprised of 
60 exons. The best characterized area of the gene is the Ras-GAP related domain (Ras-
GRD) encoded by exons 21-27a. This area is responsible for the tumor suppressor 
function of NF1. There are also 3 genes with unknown functions encoded in the reverse 
direction between exons 27b and 28. This dissertation uses mouse embryonic stem cells 
that are wild type, heterozygous or null for the NF1 gene through homologous 
recombination that replaced exon 31 (red asterisk) with a neo cassette. Neurofibromin is 
the name of the 250 kDa protein encoded by the NF1 gene (Based on Friedman, et al., 
1999).  
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Figure 1.2: NF1 manifestations. The disease Neurofibromatosis Type 1 (NF1) has very 
pleiotropic phenotypes, ranging from café au lait spots, bone abnormalities, Lisch 
nodules, optic gliomas, early puberty, and learning disabilities as well as the hallmark 
tumors called neurofibromas. Neurofibromas are usually benign, and can be discrete or 
plexiform (along the length of the nerve). Approximately 5% of plexiform tumors 
progress to malignancy, becoming malignant peripheral nerve sheath tumors (MPNST). 
This dissertation focuses on the role of NF1 in Schwann Cell development and tumor 
formation.
 
 
 
26 
 
Figure 1.3: NF1 and loss of heterozygosity (LOH) in neurofibromas. Schwann Cells 
(SC) have been found to be the initiating cell types in neurofibromas, but these tumors 
are a heterogeneous mixture of NF1+/- and NF1-/- cells, including SC, neurons, neural 
crest stem cells (NCSC), and fibroblasts, with their accompanying signals.  LOH can 
occur at different points along the SC differentiation pathway. A. Model for LOH in 
NCSC. Both neurons and SC, downstream of NCSC differentiation, are NF1-/-, while 
other cell types in tumors remain NF1+/-. B. Model for LOH in SC. Only SC are NF1-/-, 
while other cell types in the neurofibromas remain NF1+/-. (Based on Zhu, et al., 2002). 
Not all SC in tumors have LOH, however, suggesting that LOH may not be the trigger for 
tumor formation. Mutations in other genes (for e.g. p53 or retinoblastoma), injury or 
hormonal stimulation may be necessary factors.
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Figure 1.4: NF1 pathways. While neurofibromin has been shown to be part of the cAMP 
pathway in Drosophila, its most well-characterized function is as a Ras-GAP tumor 
suppressor. Following ligand/receptor binding and the resulting signal, neurofibromin 
accelerates the hydrolyzation of active Ras-GTP to inactive Ras-GDP, thus turning off 
multiple downstream pathways, such as PI3K, Rac and RAF. When the NF1 gene is 
missing or mutated, neurofibromin is not available to shut down these pathways, leaving 
them constitutively active. This can result in uncontrolled cell growth and formation of 
peripheral nerve tumors called neurofibromas.    
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Figure 1.5: Steroid hormone synthesis. The steroid hormones progesterone, testosterone, 
and 17β-estradiol are upregulated during pregnancy. All of these steroid hormones are 
originally synthesized from cholesterol and converted to the respective hormones through 
enzymatic action. Steroid hormones are ligands for classical steroid receptors that 
activate downstream genes, promoting proliferation and differentiation. Progesterone is 
the ligand for the progesterone receptor, estrogen for the estrogen receptor, and 
testosterone for the androgen receptor, although they can also rarely cross-react with low 
affinity. There are also other, non-classical steroid hormone pathways that allow for 
quick response to hormonal stimulation through secondary messengers and small G-
proteins. 
Isikoglu et al. 2002 
Posma et al. 2003 
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Figure 1.6: Steroid hormone pathways. In the classical pathway (left side), steroid 
hormones bind to classical receptors in the cell, where they induce conformational 
changes. The steroid/receptor complex then translocates to the nucleus where it 
dimerizes, binds to genes via transcription factors and hormone response elements and 
activate transcription, leading to protein production and cellular responses. In the non-
classical pathway (middle), membrane-bound or cytoplasmic steroid receptors associate 
with signaling molecules, leading to activation of PI3K or MAPK signaling cascades. In 
the steroid receptor-independent pathway (right side), novel G protein-coupled receptors 
that are unrelated to classical nuclear steroid receptors, mediate rapid, non-genomic 
signaling cascades through adenylate cyclase inhibition, cAMP production and MAPK 
activation. Other transcription factors are also involved in these pathways. (Based on 
Boonyaratanakornkit and Edwards, 2007). 
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CHAPTER II 
 
A MOUSE EMBRYONIC STEM CELL MODEL OF SCHWANN CELL 
DIFFERENTIATION FOR STUDIES OF THE ROLE OF 
NEUROFIBROMATOSIS TYPE 1 IN SCHWANN CELL DEVELOPMENT AND 
TUMOR FORMATION 
 
ABSTRACT 
The Neurofibromatosis Type 1 (NF1) gene functions as a tumor suppressor gene, 
of which one known function is to turn off the p21ras pathway by accelerating Ras 
hydrolyzation of active rasGTP to inactive rasGDP. Loss of neurofibromin (the protein 
product of the NF1 gene) in the autosomal dominant disorder NF1 is associated with 
tumors of the peripheral nervous system, particularly neurofibromas, benign lesions in 
which the major cell type is the Schwann Cell (SC). NF1 is the most common cancer 
predisposition syndrome affecting the nervous system. We have developed an in vitro 
system for differentiating mouse embryonic stem cells (mESC) that are NF1 wild type 
(+/+), heterozygous (+/-), or null (-/-) into SC-like cells to study the role of NF1 in SC 
development and tumor formation. These SC-like cells, regardless of their NF1 status, 
express SC markers, and support and preferentially direct neurite outgrowth. They are 
also capable of expressing myelin proteins.  NF1 null and heterozygous SC-like cells 
proliferate at an accelerated rate compared to NF1 wild type; this growth advantage can 
be reverted to wild type levels using an inhibitor of MAP kinase kinase (Mek). The 
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mESC of all NF1 types can also be differentiated into neuron-like cells and the behavior 
and genetic repertoires of the cells under different developmental conditions can be 
compared.  This system provides an ideal paradigm for studies of the role of NF1 in cell 
growth and differentiation of different cell types affected by NF1.  
 
INTRODUCTION 
NF1 is the most common human cancer predisposition syndrome affecting the 
nervous system (Gutmann et al. 2001). Hallmarks of NF1 include a range of symptoms 
from café au lait spots of the skin to tumors of the peripheral nervous system. Schwann 
Cells (SC) have been found to be the originating cell type in most of the benign tumors 
(Zhu et al. 2002) and can also contribute to malignant peripheral nerve sheath tumors 
(Lee et al. 2004; Miller et al. 2006). Loss of heterozygosity (LOH) is often seen in NF1 
tumors, particularly in the SC population (Zhu et al. 2002), although not all SCs in the 
tumors showed LOH  (Rutkowski et al. 2000; Sawada et al. 1996; Serra et al. 2000). 
 Neurofibromin is the protein product of the Neurofibromatosis Type 1 (NF1) 
gene. One known function of the NF1 tumor suppressor gene is to turn off the p21ras 
pathway by accelerating Ras hydrolyzation of active rasGTP to inactive rasGDP 
(Friedman et al. 1999). When NF1 is mutated, Ras is constitutively active, enabling 
affected cells to proliferate uncontrollably. This allows tumor formation, particularly in 
neural crest derived cells, such as those in the peripheral nervous system, which are 
highest in neurofibromin expression (Cichowski and Jacks 2001; Daston et al. 1992; 
Friedman et al. 1999). 
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 Studies have shown that Neuregulin-1 (Nrg-1) promotes differentiation of neural 
crest stem cells into Schwann Cells (Sieber-Blum et al. 2004). Neural crest (NC) cells are 
embryonic transitory migratory cells that differentiate into many cell types (Dorsky et al. 
2000; Kalcheim and Burstyn-Cohen 2005; Le Douarin et al. 2004; Lobsiger et al. 2002), 
including those of the peripheral nervous system affected in NF1, such as Schwann Cells 
and neurons (Cichowski and Jacks 2001; Daston and Ratner 1992; Vogel et al. 1995). 
Before becoming mature SC, which can be either myelinating or nonmyelinating, NC 
cells pass through SC precursor and immature SC stages. Myelination of SC requires the 
presence of large diameter neurites (Bunge et al. 1982; Bunge et al. 1980; Ratner et al. 
1986). 
 We have used media containing neuregulin to produce a SC differentiation 
model using mouse ES (mES) cells that have one (NF1+/-), both (NF1+/+) or neither 
(NF1-/-) functional allele, which have the potential to differentiate into many different 
cell types, including neuron-like cells (figure 2.1A) and Schwann-like cells (figure 2.1B).  
They provide an ideal system to study the effects of the environment on the gene 
expression cascades involved in the differentiation of different cell types that make 
variable levels of neurofibromin. 
 
MATERIALS AND METHODS 
Cell Types: The cell lines used for these studies include: D3 (NF1+/+) mES cell line 
(Doetschmann 1985), SKO (NF1+/-) mES cell line (Jacks et al. 1994), DKO (NF1-/-) 
mES cell  line with the NF1 gene disrupted by insertion of a neo cassette replacing exon 
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31 (Jacks et al. 1994) (figure1.1), the SW10 (NF1+/+) mouse Schwann Cell line which 
carries a temperature sensitive SV40 large T antigen and which is  grown at 37C (the 
non-permissive temperature for transgene expression) for differentiation (ATCC, 
Manassas, VA), primary rat Schwann Cells, grown as previously described (Lisak and 
Bealmear 1991).  
Media: Proliferating (ES) consisted of 81% DMEM without Phenol Red, 1% L-Glut, 
1% Pen/Strep, 1% non-essential amino acids (Gibco, Carlsbad, CA), 15% FBS (Atlanta 
Biological, Norcross, GA), 1% Sodium Pyruvate(2% stock), 7 µL/L Mercaptoethanol 
(Sigma, St. Louis, MO), 1000 U/mL ESGRO (Chemicon, Temecula, CA).  Neuronal 
Differentiation consisted of 95%F-12, 1% Pen/Strep, 1% N2, 2% B27 (Gibco), 2%   
Sodium Pyruvate (2% stock), 0.5 µg/L bFGF, 1 µg/L IL-7, 5 µg/L IGF-1 (Sigma), either 
1 µg/L CNTF (R+D) or 1 µg/L NGF (Chemicon). Schwann Cell Differentiation (SC) 
consisted of 84% -mod. MEM without Phenol Red, 1% Pen/Strep (Gibco), 10% FBS 
(Atlanta Biological), 5% 11-day chick embryo extract, 10 ng/mL NRG-1 (R&D systems, 
Minneapolis, MN). SW10 media consisted of 88% DMEM without Phenol Red, 1% L-
Glutamine, 1% Pen/Strep, 10% FBS (Atlanta Biological). Primary rat Schwann Cell 
media consisted of 90% DMEM (Gibco), 10% FBS (Atlanta Biological). Minimal 
media consisted of 87% DMEM without Phenol Red, 1% Pen/Strep, 1% L-Glutamine 
(Gibco), 10% FBS (Atlanta Biological), 1% Sodium Pyruvate (Gibco).  
Antibodies used included NF1 (rabbit polyclonal 1:50), Oct 4 (goat polyclonal 1:50 ) 
(Santa Cruz, CA), Tuj1 (mouse monoclonal 1:500) (Covance, Berkeley, CA), 
Neurofilament (rabbit polyclonal 1:400) (Chemicon, Temecula, CA), S100 (rabbit 
polyclonal 1:200 Novocastra, Newcastle Upon Tyne, UK or mouse monoclonal 1:50 
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Abcam, Cambridge, MA), GFAP (mouse monoclonal 1:400) (Chemicon), peripheral 
myelin basic protein (mouse monoclonal 1:10), Ki67 (rabbit polyclonal 1:100), (Abcam), 
tubulin (mouse monoclonal 1:200), AlexaFluor 350, 488, 594, DAPI (Molecular 
Probes, Eugene, OR), goat  rabbit-HRP (1:500) Zymed, San Francisco, CA).  
Reagents used included Histomouse (Zymed), Prolong Gold anti-fade (Molecular 
Probes), Porcine gel (Sigma), CellTiter96 cell proliferation assay (Promega). All 
antibodies were diluted in 10% donkey serum (Chemicon) in 0.1% Tween20/Phosphate 
Buffered Saline (PBS) (Sigma). 
Differentiation of mES cells into neuron-like cells: mES cells in ES medium were 
plated onto Primaria (Falcon) plates and allowed to attach overnight. After 24 hr, cells 
were washed 1x with PBS and the medium was changed to neuronal differentiation 
medium containing either 1 µg/L CNTF or 1 µg/L NGF. Undifferentiated mES cells were 
fed daily, while cells in neuronal differentiation media were fed every other day. After 5 
days’ growth, cells were labeled for expression of NF1, Oct4 (self-renewing mES cells), 
and Tuj1 (neuronal differentiation).  
Differentiation of mES cells into SC-like cells: mES cells in ES medium were plated 
onto Primaria (Falcon) plates and allowed to attach overnight. After 24 hr, cells were 
washed 1x with PBS and the medium was changed to SC medium. Cells were fed every 
other day and passed when confluent (~every 5-6 days). After one week, cells had the 
appearance of SC-like cells (flat and spindly), and proliferation rate was assessed and 
found to have decreased. After 2 weeks in SC-differentiation media cells were examined 
by RTqPCR for changes in NF1 expression and immunoassayed for S100 and GFAP 
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expression. After one month, cells were assayed for the ability to initiate and direct 
neurite outgrowth and to produce myelin. Cells have been frozen and thawed and remain 
proliferative and SC marker-expressing over at least 20 passages.  
Immunocytochemistry (ICC): 40,000 cells were plated onto 0.1% porcine gel-coated 
(Sigma) coverslips (Corning, Corning, NY) and grown overnight. Cells were then fixed 
in 4% paraformaldehyde (Sigma), permeabilized in 0.2% TritonX100 (Sigma), stained 
and mounted onto Superfrost plus slides (Fisher, Pittsburgh, PA). The Zymed 
Histomouse kit was used according to the manufacturer’s instructions for the non-
fluorescent ICC using mouse monoclonal antibodies. Fluorescence micrographs were 
taken with an Olympus BX-51 microscope, and non-fluorescent micrographs with Nikon 
ACT-1 software on a Leitz Diavert inverted microscope. 
RTqPCR: RTqPCR was performed using primer pairs designed using the Beacon 
designer  program (BioRad, Hercules, CA), with target Ta at 55º C, length 18-22 bp and 
amplicon size 100 – 200. SW10 gene expression was normalized to GAPDH, while ES 
cell fold changes with SC-like differentiation were compared by dividing SC 
differentiated cell expression by proliferative cell expression. Quantification of SC 
marker expression was assayed at the time points listed. To assay SC-like cells myelin 
gene upregulation in the presence of neurons, day E5 chick SAGs were excised and 
added at time points listed and grown an additional seven days before RTqPCR analysis. 
Total RNA from the samples was extracted using Qiagen mRNA Kit 74106 (Qiagen, 
CA). RT-PCR was performed as follows: cDNA was synthesized from 2 µg total RNA 
by reverse transcription using Super Script III transcriptase (Invitrogen, Carlsbad, CA) 
and oligo dT primer. The PCR conditions consisted of an initial denaturation at 94C for 
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1min, 94C for 1 min, 55C for 30 sec and 74C for 30 sec and 34 cycles and final 
extension at 72C for 5 min and 4C holding temperature. The PCR products were 
separated on 2.0% agarose gels and visualized using ethidium bromide (staining) under 
UV light.  
PCR primers: NF1: forward AGTTTCTCTCCTCGCTGGTCTTC reverse 
CGTTTCCTGCCACCCGTTTG; Oct4: forward CCAACGAGAAGAGTATGAGG 
reverse CTGAGTAGAGTGTGGTGAAG. α4integrin: forward 
GAATCTCCTCCACCTACTCACAG reverse CCAACGGCTACATCAACATATCC; 
Cad19: forward GGAGGAGACAGACAAGATG reverse 
TGAAGGAGTGATGGTAGATG; PMP22: forward GCTCTGTTCCTGTTCTTCTG 
reverse TGCCTCACTGTGTAGATGG; MBP: forward 
AGACCCTCACAGCGATCCAAG reverse AGTCAAGGATGCCCGTGTCTC; 
α1β1integrin: forward CAGTGAATGGCAACAATGAAG reverse 
ATCAGCAGCAAGGCAAGG 
Proliferation rates of mES cells during SC-like differentiation: 30,000 cells per well 
were counted and plated onto Primaria (Falcon) 24-well plates. After indicated days’ 
growth, proliferation was assayed using immunocytochemistry with the Ki67 antibody, 
which recognizes cells in active cell cycle. If indicated, E5 chick statoacoustic ganglions 
(SAGs), cells which are destined to innervate the inner ear, were excised and added to the 
plate and grown an additional three days before assay was performed. The percentage of 
Ki67 positive cells as compared to total cell number was used to determine proliferation 
rate. Microsoft Excel was used to graph and analyze the data. Data are expressed as mean 
+/- SD. 
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Proliferation rates of mES cells after addition of U0126 Mek inhibitor: To determine 
if the Ras pathway is involved in overproliferation of NF1+/- and NF1-/- SC-like cells 
10,000 cells per well were plated onto 96-well Primaria plates. After one hour, either 4 
µM U0126 (Mek inhibitor) or ethanol (vehicle control) were added to wells and cells 
were allowed to grow three days. Proliferating cells were determined using the 
CellTiter96 (Promega) proliferation assay and absorbance was measured at 492 nm by 
microplate reader (Fisher).  Absorbance is directly proportional to number of actively 
metabolizing cells. 
Statoacoustic ganglion-supported neurite outgrowth and directional 
outgrowth: To test for SAG-supported neurite outgrowth, statoacoustic ganglions 
(SAGs) from E5 chick embryos (Bianchi et al. 2005a; Bianchi et al. 2005b) were excised 
and plated onto undifferentiated mES cells (D3, SKO, or DKO), SC-differentiation mES 
cells (D3SC, SKOSC, DKOSC), or SW10SC cells. After 5 days, cultures were assayed 
for presence or absence of neurite outgrowth (Neurofilament positive) as well as the 
percentage of the area occupied by SAG-neurite positive cells. The total area of SAG 
neurite positive cells and outgrowth was quantified using Metamorph software (Universal 
Images Corp) threshold image analysis by determining the percent of Neurofilament-
stained cell area compared to the total area. To determine if SAG neurite outgrowth was 
preferentially directed towards SC-differentiated cells, we excised and plated SAGs on 
culture dishes to which undifferentiated mES cells and SC-like cells were subsequently 
added on coverslips in two different quadrants of the plate equidistant from the SAG 
center. We first allowed the SAGs to attach overnight and then added two coverslips, one 
containing undifferentiated mES cells and the other coverslip containing SC-like cells, 
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with the coverslips placed equidistant from the SAG center. These cultures were grown 
for five days and assessed for a) preferential direction of neurite outgrowth, b) any 
contact between the mES cells (SC-differentiated or undifferentiated) and the neurites. 
Neurites in each half of the plate were assessed for extension toward each cell type 
(undifferentiated vs. SC-differentiated). 
Quantification of SAG neurite outgrowth branching and intersections: In 
order to differentiate and quantify any differences between NF1+/+ WT, NF1+/- 
heterozygous and NF1-/- null SC-like cells’ affect on SAG neurite branching, we 
overlaid a grid onto SAG/SC-like cell co-culture fluorescent figures (n=12) stained with 
Tuj1 for neurite outgrowth and counted the number of intersections in random sections. 
Microsoft Excel was used to graph and analyze the data. Data are expressed as mean +/- 
SD.  
 
RESULTS 
mES cells assume a SC-like morphology and sequentially express SC lineage 
markers following growth in neuregulin-containing SC media, regardless of their 
NF1 expression level that increased in NF1+/+ and NF1+/- SC-like cells.  
 We exposed the (D3 NF1+/+, SKO NF1+/-, and DKO NF1-/-) mES cells to a 
medium (SC media) designed to enhance Schwann Cell differentiation. After growth for 
one week in SC media, fed every second day, all cell types (D3 NF1+/+, SKO NF1+/-, 
and DKO NF1-/-) flattened out and took on the spindly appearance characteristic of SC 
and tested positive by immunocytochemistry (ICC) for the expression of two different SC 
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proteins-S100 and GFAP, as did the SW10 mouse SC and the primary rat SC (figure 
2.1B, compare with mouse SC line SW10 and primary rat SC in bottom rows). Hereafter, 
SC-like differentiated mES cells will be referred to as D3SC, SKOSC, and DKOSC, for 
D3 (WT-NF1+/+), SKO (single knock out-that is missing one NF1 allele; NF1+/-), or 
DKO (double knock out; NF1-/-).  
 Since exon 31 was replaced by a neo cassette in these mutant NF1 alleles (Jacks 
et al. 1994) (figure 1.1), we were able to target this area to design primers to quantify 
NF1 expression. RTqPCR confirmed NF1 expression in undifferentiated D3, and SKO 
cells, while NF1 was not expressed in DKO cells (figure 2.1C).  NF1 expression levels 
were set at 100% in D3 cells. This level was used to determine NF1 expression levels of 
SKO (55%) and DKO (0%) cells, and all SC-differentiated cells. NF1 expression was 
upregulated ~150% after two weeks in SC-differentiation media in D3SC (from 100% to 
152%) and SKOSC (from 55% to 85%) cells, while remaining at undetectable levels in 
DKOSC (figure 2.1C). NF1 was also expressed in SW10 SC and primary mouse SC (not 
shown). 
 To determine whether differentiating cells followed all the characteristic stages of 
differentiation into mature SC, we also tested gene expression at various stages of 
differentiation from undifferentiated ES cells to mature SC, using as markers genes 
characteristic for these stages according to reports in the literature (Jessen and Mirsky 
1991; Lobsiger et al. 2002). These included the following stages: Undifferentiated ES 
(Oct4), neural crest (alpha4integrin), SC progenitor (Cad19), immature SC (PMP22), to 
mature myelinating SC (myelin basic protein-MBP) and unmyelinating SC 
(alpha1beta1integrin). We found that Oct4 (figure2.2A) was most highly expressed on 
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day 0 of differentiation in culture, becoming undetectable with culture in SC-
differentiation media. DKO and SKO cells expressed lower levels of Oct4 on day 0 than 
D3 cells. By contrast, markers along the SC-differentiating pathway, such as 
alpha4integrin (figure 2.2B) and Cad19 (figure 2.2C) were more gradually upregulated, 
while genes characteristic of more mature SCs, including PMP22 (figure 2.2D) whose 
expression persists through myelination, MBP (figure 2.2E) and alpha1beta1integrin 
(figure 2.2F) generally needed the presence of SAG neurites to stimulate their highest 
expression levels (figure 2.2 and table 2.1).  An exception to this was in DKOSC (NF1-/-) 
cells, in which MBP was seen to be downregulated in the presence of SAG neurites.  
Overproliferation of NF1-deficient or null SC-like cells can be reduced by Mek 
inhibition 
 NF1+/+ mES cells had higher proliferation rates than NF1 deficient mES cells 
(figure 2.3A, day 0), but after day 9 in SC-differentiating conditions NF1 deficient cells 
had higher proliferation rates than NF1+/+ cells (figure 2.3A, days 18, 28), presumably 
due to constitutively active Ras. D3SC cells’ proliferation rate was comparable to SW10 
SC (47%). As quiescence is expected for SC in the presence of neurites, following chick 
statoacoustic ganglion (SAG) addition to the culture, NF1+/+ cells (D3SC, SW10) 
became less proliferative, with 34% and 29% actively cycling cells, respectively (figure 
2.3A, rightmost set). By contrast, most SKOSC (70%-60%) and DKOSC (77%-66%) 
cells remained in active cell cycle (figure 2.3A). Ki67 expression revealed non-axonal 
associated clumps of proliferative SKOSC (NF1+/-) and DKOSC (NF1-/-) cells among 
the SAG neurites (figure 2.3B). 
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 Overproliferation of SKOSC and DKOSC cells could be reversed to WT levels by 
the addition of 4 µM U0126, a Mek inhibitor (Favata et al. 1998), which is a component 
of the Ras pathway. Since this pathway is constitutively active following the loss of NF1 
function, our results indicate that the Ras pathway is likely to be involved in this 
overproliferation (figure 2.3C).   
SC-like differentiated mES cells can support and direct neurite outgrowth from 
primary chick statoacoustic ganglia 
 We found that neurite outgrowth and complexity of neurite formation and 
branching in chick statoacoustic ganglia (SAG) was increased in the presence of mES 
cells that had become SC-like (figure 2.4).  Excised SAGs from E5 chick embryos plated 
onto undifferentiated mES (D3, SKO or DKO) cells, SC-differentiated (D3SC, SKOSC, 
or DKOSC) mES cells or SW10 SC cells had different neurite outgrowth patterns. We 
found that undifferentiated mES cells, regardless of their NF1 genotype and NF1 
expression level, did not support neurite outgrowth or myelin production, while SAGs 
grown on any of the SC-differentiated cells (figure 2.4A) supported neurite outgrowth 
over 5 days, with branching processes never seen in cultures of SAGs alone (figure 
2.5B), or on defined substrates such as poly-L-lysine, even in neurite outgrowth 
promoting medium (Bianchi et al. 2005b). Sometimes outgrowth was so extensive, 
especially in NF1 deficient and NF1 null cells, that it obscured our ability to discern the 
shape of the original SAG (especially see SKOSC figure 2.4A middle row to the right). 
We next determined if the SAGs needed physical cell-cell contact with the SC-like cells 
or if the cells could affect the directionality of the neurite outgrowth without direct 
contact. Excised SAGs were plated on culture dishes on which undifferentiated mES cells 
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(figure 2.4C, on the left) and SC-like cells (figure 2.4C, on the right) were subsequently 
added equidistant from the SAG center on coverslips in two different quadrants of the 
plate. After 5 days growth, in every case the SAGs preferentially extended neurites 
toward/over the SC-like mES cells, and almost invariably veered around any 
undifferentiated colonies without making contact (figure 2.4C). Although 
undifferentiated ES cells did not seem to inhibit the initiation of neurite outgrowth, 
neurites that had begun to grow out from the side of the explant nearer the 
undifferentiated ES cells, turned and extended towards the differentiated SC-like mES 
cells (n=4 for each cell type). Over the 5 day observation period, the cells of both types 
continued to proliferate (ES cells at a faster rate than the SC-like cells) (figure 2.4C), 
with cells migrating off the coverslip, so that the undifferentiated cells sometimes grew 
very near to the SAGs, causing the neurites to veer around the colonies (purplish 
mounds) of undifferentiated mES cells (figure 2.4). When neurite outgrowth in the half 
plate that contained SC-differentiated mES cells was compared to that in the other half of 
the plate, occupied by undifferentiated mES cells, the direction of neurite outgrowth was 
always found to be towards the SC-like cells; neurites that began by traveling toward the 
undifferentiated cells changed course and veered towards the SC-like cells in every case 
(n=5). Even though the cells were grown without LIF (ES) or Nrg-1 (SC) supplements to 
the medium, they kept their respective morphological appearance over the 5 days of the 
assay.  
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All SC-like mES cells expressed myelin in cells near axons, while only NF1-deficient 
cells showed plate overgrowth and greater SAG neurite extension and branching 
 To assay whether the SC-like cells were maturing, we determined if the SC-like 
mES cells would express myelin protein in the presence of SAG neurons. We plated and 
cultured the SAGs and either SC-like cells or SW10 SC for five days, after which the 
cells were labeled for either PNS myelin protein expression using a mouse monoclonal 
antibody to peripheral myelin and the Histomouse kit (figure 2.5A, left column), or 
analyzed for a combination of PNS myelin (for SC), Neurofilament (for neurites) and 
DAPI (nuclear stain) (figure 2.5A, right column). With the Histomouse kit, we were able 
to demonstrate that the SC-like cells and SC that expressed myelin clustered around what 
appear to be axons (figure 2.5A, left column). In SKOSC and DKOSC, cells farther away 
from the neurites did not stain for myelin expression and became very confluent. In the 
two NF1+/+ cell lines (D3 and SW10), myelin positive cells associated with the axons, 
but there was very little growth on the rest of the plate. We wanted to visualize the 
association of SC-differentiated cells to the SAG neurites in a single preparation.  
Therefore, fluorescent secondary antibodies to a neural marker, Tuj1, for SAG neurites 
and DAPI nuclear stain for SC-differentiated cells were used concomitantly. In these 
cultures, NF1+/+ cells (D3SC, SW10) associated only with SAG neurites, while clusters 
of non-axon associated NF1+/- (SKOSC) and NF1-/- (DKOSC) SC-like cells were also 
seen (figure 2.5A, right column). To be sure that cells that may have been excised with 
the SAG were not those producing the observed myelin expression, we also grew SAGs 
on plates without any additional cells in the same medium used to culture SC or SW10 
cells. SAGs or associated cells did not express myelin under any of these conditions 
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(figure 2.5B). Most SAGs did not extend any neurites at all under these conditions (figure 
2.5B, right); occasionally neurite extension was initiated, but these neuritic processes 
were confined to areas around the SAG, without extending onto the plate (figure 2.5B, 
left). An example of extensive SAG neurite branching seen exclusively over SC-like 
differentiated cells is also shown (fig, 2.5B, bottom). 
Next, we wanted to determine if there were differences in the area of the plate 
occupied by neurons or neurites that varied with levels of NF1 expression. To quantify 
the amount of neurite outgrowth, we used the Metamorph software program to measure 
the percentage of the area covered by neurite outgrowth, as represented by Tuj1 or 
neurofilament antibody staining, to the total area. We found that D3SC cells stimulated 
SAGs and their associated neurites to cover significantly more area than SKOSC cells or 
DKOSC cells (figure 2.5C). Although the D3SC cells stimulated more total 
neuron/neurite-positive area, much of this area was seen to be in clumps of SAGs 
themselves rather than in neurite extensions over the SC lawns. SAGs grown in the 
presence of SKOSC and DKOSC cells visually appeared to have more neurite branching 
over the areas of the plate with underlying SC-like cells (figure 2.5B, bottom). When 
clumps of somata were subtracted from the total area and only the extent of neurite 
outgrowth and branching was measured, DKOSC and SKOSC cells had higher 
percentages of neurite positive area compared to the total area occupied by antibody-
positive neuronal cells/and/or neurites (figure 2.5C).  They also had more SC-like mES 
cell proliferation not associated with SAG neurites (figure 2.5A). In order to differentiate 
between NF1+/+ WT, NF1+/- heterozygous and NF1-/- null SC-like cells’ effect on SAG 
neurite branching, we overlaid a grid onto various figures and counted the number of 
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SAG neurite intersections in random sections. Visually, NF1+/+ SC-like cells appeared to 
elicit thicker, more parallel SAG neurite outgrowth than either NF1+/- or NF1-/- SC-like 
cells, which appeared more highly branched (figure 2.6A). Quantification of intersecting 
neurites revealed that NF1+/- and NF1-/- SC-like cells elicited significantly greater 
primary neurite branching compared to NF+/+ SC-like cells, but not between NF1+/- and 
NF1-/- SC-like cells (figure 2.6B).  
 
DISCUSSION 
 We sought a model for the role of NF1 in SC development in which the level of 
neurofibromin could be controlled and comparisons made among cells with different 
level. mES cells that were wild type, heterozygous or mutant for the NF1 gene were 
chosen as the cell source (Jacks et al. 1994). In this study, mES cells were differentiated 
into SC-like cells in order to more closely approximate the originating tumor cell type 
(Zhu et al. 2002).  Since Neuregulin-1 (Nrg-1) had been found to promote differentiation  
of neural crest stem cells into Schwann Cells (Sieber-Blum et al. 2004), we used a 
modified version of Nrg-1 containing media to preferentially direct these mES cells into 
SC-like cells.   
 By the end of one week in Nrg-1-containing SC media, the mES cells had 
flattened out and changed their shape to more closely resemble SC morphologically. All 
cell types also slowed their rate of proliferation, suggesting a change from a more rapidly 
growing undifferentiated ES cell rate to cells with a similar growth pattern to SCs. To 
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distinguish the undifferentiated mES cells from the SC-like cells, we refer to SC-
differentiated cells as D3SC (NF1+/+), SKOSC (NF1 +/-), or DKOSC (NF1-/-). 
 After two weeks in SC medium, D3SC, SKOSC, and DKOSSC all expressed two 
different SC proteins-S100 and GFAP, demonstrated by ICC.  NF1 expression in 
undifferentiated ES cells (D3-NF1+/+, and SKO-NF1+/-) was upregulated upon 
differentiation into SC-like differentiated cells, consistent with the known higher 
expression of NF1 in SC, while DKO (NF1-/-) cells’ level of NF1 expression remained 
undetectable. To determine if differentiation from undifferentiated ES cells to SC 
required passage through intermediate stages, we tested these cells over a three week 
period in culture for expression of stage-specific markers of the SC differentiation 
lineage.  
 Oct 4, a marker of undifferentiated ES cells, was most highly expressed at day 0 
of differentiation in all cell types, although expression was highest in D3 (NF1+/+) cells, 
and was then downregulated to undetectable levels. This may be because SKO and DKO 
mES cells seem to be more difficult to retain as undifferentiated in culture, with colonies 
forming a more irregular border than D3 (NF1+/+) mES cells (figure 2.1A and personal 
observation). 
By contrast, alpha4integrin (neural crest), Cad19 (SC precursors), PMP22 (immature 
SC), MBP (myelinating SC) and alpha1beta1integrin (unmyelinating SC) were expressed 
at undetectable/very low levels in undifferentiated ES cells, but became more highly 
expressed as differentiation progressed.  
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 Earlier SC lineage markers reached their highest level of expression over time 
when grown in SC-differentiation medium, although all the cells on the culture plate did 
not appear to differentiate at the same time. This could be due to the observation that 
undifferentiated mES cells grow in large clumped colonies rather than in flat monolayers. 
This could cause the outer cells, with greater exposure to the differentiation media, to 
differentiate more rapidly than the inner cells of the mounds. 
 In vivo, there is a close relationship between neurons and SCs (Bunge et al. 1980; 
Lobsiger et al. 2002; Wood 1976). Myelinating SC wrap around one or more individual 
large-diameter axons; non-myelinating SCs insulate small-diameter neuron bundles that 
are imbedded in the cytoplasm and surrounded by plasma membrane (Lobsiger et al. 
2002). SCs are unlikely to express myelin unless they are in the presence of neurons 
(Coman et al. 2005; Lobsiger et al. 2002).Genes that are upregulated later in SC 
development (PMP22), as well as mature SC genes expressed in myelinating (MBP) and 
unmyelinating (alpha1beta1integrin) SC were expressed at their highest levels following 
exposure to SAG neurites, with the exception of DKOSC cells’ MBP expression, which 
was decreased in the presence of SAGs. This could be due to overproliferation and 
aberrant association of NF1-/- SC with axons, and because SAGs showed greater 
branching of neurites when grown in co-culture with DKOSC cells, which may result in 
smaller diameter axons that are not myelinated.  
 In agreement with NF1’s function as an inactivator of the Ras pathway (Friedman 
et al. 1999; Kogut et al. 2007; Mattingly et al. 2006), DKOSC (NF1-/-) and SKOSC 
(NF1+/-) cells showed significantly increased cell proliferation rates compared to D3SC 
cells, and aberrant proliferative cells unassociated with SAG neurites in co-culture. When 
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we inhibited this pathway using U0126, a Mek inhibitor (Favata et al. 1998; Kogut et al. 
2007; Mattingly et al. 2006), we were able to return proliferation rates to WT levels. This 
indirectly indicates that the inability to hydrolyze Ras effectively resulted in 
overproliferation. D3SC (NF1+/+) cells, already able to hydrolyze and inactivate Ras, 
were unaffected by U0126 addition.     
 To stimulate myelin expression and to determine axonal association, we examined 
the ability of the mES-derived SC-like cells to myelinate the chick statoacoustic ganglion 
(SAG), which innervates the inner ear, the individual neurites of which are myelinated 
(Bianchi et al. 2005b; Whitlon et al. 2006). It has been suggested that direct interaction 
with SC serves as a substrate for neuron attachment and growth, such as with SAGs 
(Whitlon et al. 2006). We found that neurite outgrowth in SAGs was increased in the 
presence of mES cells that had become SC-like, as compared to undifferentiated mES 
cells, MEF cells (not shown) or in media alone without an underlying cell layer. This was 
true regardless of their NF1 genotype and NF1 expression level, although NF1 deficient 
cells exhibited more elaborate branching. The SAGs grown on SC-like cells supported 
neurite outgrowth over the 5 day culture period, sometimes in NF1 deficient and null 
cells even to the extent that we were unable to discern the shape of the original SAG 
explant. Directional neurite outgrowth was also extensive when we excised and plated the 
SAGs on culture dishes on which undifferentiated mES cells and SC-like cells were 
subsequently added on coverslips in two quadrants of the plate equidistant from the SAG. 
The SAGs in every case (n=5) extended neurites toward/over the SC-like mES cells, 
regardless of their NF1 status. While undifferentiated ES cells did not seem to inhibit the 
initiation of neurite outgrowth, neurites that had begun to grow out from the side of the 
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explant nearer the undifferentiated ES cells, turned and extended towards the 
differentiated SC-like mES cells, suggesting either a chemoattractant signal from the SC-
like cells or a repulsive signal from the undifferentiated mES cells.  Even though the cells 
were grown without LIF (ES) or Nrg-1 (SC) supplements to the medium, they kept their 
respective morphological appearance over the 5 days of the assay.  
 We then determined that SC-like mES cells could express myelin protein and 
associate with axons in the presence of SAG neurons. SC-like cells and SC that expressed 
myelin clustered around the neurite processes. In SKOSC and DKOSC, in addition to 
neurite-associated cells, non-associated proliferative cells farther away from the axons 
did not express myelin and became very confluent. In the two NF1+/+ cell lines (D3 and 
SW10), myelin-positive cells clustered around the axons, but there was very little cell 
growth on the rest of the plate, again suggesting a possible chemoattractant component 
produced by the SC-like cells or the SAG itself. Axonal association was also seen in SC-
like cells closer to the neurites when we used fluorescent secondary antibodies to 
visualize both the neurites and the SC-like cells. In addition, large numbers of NF1-
deficient cells also grew without axonal association. Although during this short culture 
period we could not document SC-like cells wrapping around neurites, that is most likely 
due to the plates becoming very confluent by day 5, since undifferentiated mES cells had 
to be plated at a high enough density to avoid spontaneous differentiation, and did not 
allow for the one month or more that must ensue before wrapping has been documented 
in culture (Ratner et al. 1986). When SAGs were grown on plates without any additional 
cells, the chick SAGs or associated non-neuronal cells did not express myelin under any 
of the conditions tested in these experiments. This was done to confirm that the myelin 
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protein was expressed from the SC-like cells rather than any cells excised with the SAG. 
Occasionally neurites were initiated, but they were mostly confined to areas around the 
SAG, without extending into the plate, also suggesting that a chemoattractant could be 
secreted from the SC-like cells. Cells grown on mouse embryonic fibroblasts also did not 
support neurite outgrowth or myelination (not shown). 
 When we quantified neurite outgrowth, we found that while NF1+/+ (D3SC) SC-
like cells had larger total neurite-positive areas, much of this was due to SAG clumps. 
When neurites only were measured, NF1+/- (SKOSC) and NF1-/- (DKOSC) SC-like 
cells elicited greater SAG neurite outgrowth and considerably greater branching of SAG 
neurites. More neurites intersecting would leave thinner diameter axons that are more 
characteristic of a non-myelinating phenotype. SC that wrap around neurons greater than 
1µM diameter myelinate, while SC associated with axons smaller than 1µM diameter are 
non-myelinating. This could explain why MBP (myelinating SC) expression was higher 
in D3SC/SAG co-cultures and alph1beta1 (associated with non-myelinating SC) 
expression was higher in SKOSC/SAG and DKOSC/SAG co-cultures. 
 From our experiments we conclude that NF1 (+/+, +/- or -/-) mESC can 
differentiate in vitro into Schwann Cell (SC)-like cells that express appropriate SC genes 
in the expected order of expression for SC maturation, support and preferentially direct 
primary ganglion neurite outgrowth, and express myelin in cells near neurites. In vitro, 
NF1+/+ SC-like cells (D3SC) are more likely to express myelinating SC genes, and 
become quiescent in the presence of SAG neurites at a rate similar to SW10 mouse SC. 
NF1+/- (SKOSC) and NF1-/- SC-like cells (DKOSC) are more likely to stimulate greater 
neuron migration, neurite outgrowth and branching, express non-myelinating genes, and 
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slightly reduce proliferation in the presence of SAG neurites. Overproliferation of NF1 
deficient (SKOSC) and null (DKOSC) SC-like cells can be reduced to NF+/+ (D3SC) 
levels by the addition of a Mek inhibitor, indirectly indicating Ras pathway involvement. 
This paper is the first of which we are aware that shows that mES cells can be 
preferentially directed down the Schwann Cell pathway. Since all three mES cell lines, 
regardless of their NF1 status, can respond by differentiating into SC-like cells, these 
cells can be used in further studies of the function of SC with varying levels of 
neurofibromin in tumor formation and growth. 
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Figure 2.1: Undifferentiated mES cells that express various levels of neurofibromin grow 
in mounds and can be differentiated into neuron-like cells and SC-like cells. NF1 
expression is upregulated following SC differentiation. Cell Types are listed in the 
leftmost box of each row. A: Self-renewing mES cells express Oct 4 (blue). NF1 
expression (green) is strong in D3 (NF1+/+) cells, weakly expressed in SKO (NF1+/-) 
cells, and not expressed in DKO (NF1-/-) cells. Tuj1 (red), a neuronal marker, was 
weakly expressed around the edges of colonies, showing some differentiation in 
peripheral cells (left). After 5 days growth in neuronal differentiation media, Tuj1 
expression was strongly observed in the neurites of neuronal-like cells, while Oct 4 
expression decreased and was only seen in some clumps, perhaps due to the inability of 
CNTF or NGF to diffuse into the middle of these large colonies (center and right). B: 
Left column: morphology of mES cells, which take on a flat and spindly appearance after 
one week’s growth in SC differentiation media, similar to the morphology of the SW10 
SC line and primary rat SC. (32x magnification with phase 1 filter). Middle column 
shows expression of S100 and right column shows GFAP expression (40x 
magnification). C: RTqPCR shows NF1 expression in SKO cells is 55% that of D3 cells, 
while expression in DKO cells is undetectable. After SC differentiation, NF1 expression 
increased ~150% in both D3SC cells and SKOSC cells, while remaining undetectable in 
DKOSC cells 
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Figure 2.2: Expression of SC lineage markers are upregulated with time. A: Oct4, 
expressed in undifferentiated ES cells, is highly expressed on Day 0 in all cell types, 
especially D3 (NF1+/+) but is not detectable with SC-differentiation. B: α4integrin, 
expressed in neural crest and SC precursors, C: Cad19, expressed in SC precursors, and 
D: PMP22, expressed in immature SC, as well as myelinating and non-myelinating SC, 
are either undetectable or expressed at very low levels in undifferentiated ES cells but are 
all detectable following culture in SC differentiation media. E, F: Two markers of mature 
SC are upregulated in the presence of SAG neurites (starred columns). MBP, expressed 
in myelinating SC, is more highly upregulated in D3SC (NF1+/+) cells, while 
α1β1integrin, expressed in non-myelinating SC, is most highly expressed in DKOSC 
(NF1-/-) cells. 
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Figure 2.3: Proliferation rates differ between cell types based on NF1 genotype. A: 
NF1+/+ mES cells have higher proliferation rates, determined by percentage of cells in 
active cell cycle (Ki67+) than NF1 deficient mES cells (day 0). By contrast, SC-like 
differentiated NF1 deficient cells had higher proliferation rates than NF1+/+ cells. By 28 
days in SC-differentiation media, D3SC cells had the same percentage (47%) of cells in 
cell cycle as SW10 SC, while SKOSC and DKOSC cells were hyperproliferative (70% 
and 77%, respectively). Following addition of SAG cells to the culture, NF1+/+ cells 
(D3SC, SW10) showed reduced proliferation, with only about 30% of their cells in cell 
cycle, while NF1+/- (SKOSC) and NF1-/- (DKOSC) still had over 60% of cells in cell 
cycle. B: Staining for Ki67-positive cells reveals proliferative clumps of non-axon 
associated SKOSC and DKOSC cells (100x magnification) C: Overproliferation of 
NF1+/- and NF1-/- SC-differentiated cells is dependent on Ras signaling. SKOSC 
(NF1+/-) and DKOSC (NF1-/-) cells proliferate at a significantly increased rate over that 
of D3SC (NF1+/+) cells (green columns), presumably due to the unavailability of NF1 to 
accelerate inactivation of the Ras pathway. This overproliferation can be decreased to 
wild type levels through application of 4 µM U0126, an inhibitor of the Mek component 
of the Ras pathway (red columns).  
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Figure 2.4: mES cells which had been differentiated into SC-like cells, but not 
undifferentiated mES cells, attracted neurite outgrowth from primary neurons. Cell types 
are listed in each box. A: E5 chick SAGs were excised and plated onto the cell types 
listed, grown for 5 days and labeled with antibodies to Tuj1. There was little or no neurite 
outgrowth toward undifferentiated mES cells, but extensive outgrowth toward SC-like 
cells (Photographs of undifferentiated cells are at 20x and SC-like cells are at 10x 
magnification) B: When SAGs were plated on the TC substrate equidistant between 
coverslips plated with undifferentiated mES cells (left side) and SC-like differentiated 
mES cells (right side), neurite outgrowth was preferentially directed towards the SC-like 
cells. When undifferentiated mES cells migrated off the coverslips towards the SAGs, the 
neurites actively avoided the colony (seen as purple mounds). When neurite outgrowth 
was initiated on the side on which the undifferentiated cells were plated, the neurites 
turned and continued growing towards the SC-like cells (4x magnification). 
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Figure 2.5: SC-like cells stimulate neurite outgrowth, express myelin protein and 
associate with neurites when grown in the presence of primary neurons. A: E5 chick 
SAGs were plated onto SC-like mES cells or SW10 SC and grown for 5 days, after which 
they were fixed and stained. Cells were observed to cluster around neurites and expressed 
myelin protein (left column). While D3SC and SW10 cells (both NF1+/+) associated 
only with the neurites, SKOSC (NF1+/-) and DKOSC (NF1-/-) cells grew to confluency 
over the entire plate (left column, 10x magnification, right column 100x magnification). 
Some SAG neurites grown with SC-like cells showed extensive branching (B, bottom 
right) B: Excised SAGs grown in media alone without an underlying cell layer did not 
express myelin. Neurite outgrowth was either confined around the SAG (left) or was not 
observed (right) (40x magnification) C: Amount of SAG neurite outgrowth is dependent 
on NF1 status of underlying cells. Total positive area is greater in SAGs grown with 
D3SC (NF1+/+) cells, but neurite extension area is greatest in DKOSC cells. This is 
attributed to greater migration and neurite outgrowth and branching of the SAG cells in 
the presence of SKOSC (NF1+/-) and DKOSC (NF1-/-) cells. Areas of neurite-positive 
cells were measured using Metamorph threshold image analysis.
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Figure 2.6: Primary neuron processes intersect more frequently when grown in the 
presence of NF1-deficient SC-like cells. A. In order to differentiate between NF1+/+ WT, 
NF1+/- heterozygous and NF1-/- null SC-like cells’ effect on SAG neurite branching, we 
overlaid a grid onto various figures (Tuj1-stained for visualization of neurite outgrowth 
after 5 days’ co-culture, 100x magnification) and counted the number of SAG neurite 
intersections in random sections. NF1+/+ SC-like cells elicited thicker, more parallel 
SAG neurite outgrowth more characteristic of myelinating SC. B. Quantification of these 
calculations revealed that NF1+/- and NF1-/- SC-like cells elicited greater primary 
neurite branching. More neurites intersecting would leave thinner diameter axons that are 
more characteristic of a non-myelinating phenotype. There were significantly greater 
neurite intersections on SAGs grown on NF1+/- and NF1-/- SC-like cells compared to 
NF+/+ SC-like cells, but not between NF1+/- and NF1-/- SC-like cells. 
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Table 2.1: The expression levels of genes involved in differentiation from ES cells to SC 
change over time. D3 (NF1+/+), SKO (NF1+/-), and DKO (NF1-/-) cells were tested at 
the time points listed with or without the presence of chick statoacoustic ganglions 
(SAGs). Timing of greatest expression for each of the genes tested is listed in the 
indicated middle column. Undifferentiated mES marker Oct4 was expressed most highly 
on differentiation day 0, and remained undetectable thereafter. Genes involved in NC 
differentiation (alpha4integrin), and SC precursors (Cad19) increased expression during 
exposure to SC-differentiation media, while PMP22, expressed in immature SC 
throughout myelination, as well as mature markers of myelinating (MBP) and 
unmyelinating (alpha1integrin) SC were expressed more highly in the presence of chick 
SAG neurites. An exception to this was reduced MBP expression in DKOSC cells grown 
with SAGs. 
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CHAPTER III 
 
INFLUENCE OF HORMONES AND HORMONE METABOLITES ON THE 
GROWTH OF SCHWANN CELLS DERIVED FROM MOUSE EMBRYONIC 
STEM CELLS AND TUMOR CELL LINES EXPRESSING VARIABLE LEVELS 
OF NEUROFIBROMIN 
  
ABSTRACT 
 Loss of neurofibromin, the protein product of the tumor suppressor gene 
Neurofibromatosis Type 1 (NF1), is associated with neurofibromas, which are comprised 
largely of Schwann Cells. The number and size of neurofibromas in NF1 patients has 
been shown to increase during pregnancy. Mouse embryonic stem cells with varying 
levels of neurofibromin were differentiated into Schwann-like cells. These cells and NF1 
tumor cell lines derived from a malignant and a benign human tumor were used to study 
proliferation in response to hormones. Estrogen (ER) and androgen (AR) receptors 
showed very low/no expression in the NF1+/+ cells, low levels of expression in NF1+/-
cells, and more intense expression in NF1-/-cells. Assays on mouse tissues in which cre 
recombinase targeted the loss of NF1 in Schwann Cell lineage cells showed similar ER 
and AR expression. Expression of progesterone receptor (PR), however, was also robust 
in NF1-deficient tissues, suggesting an important role for the tumor microenvironment. 
We have also found that an E2 metabolite that is not ER-dependent, 2Methoxyestradiol 
(2ME2), is cytotoxic to the NF1-/- malignant tumor cell line, and inhibits proliferation in 
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the other cell lines. 2ME2 or its derivatives could provide new treatment avenues for NF1 
hormone-sensitive tumors at times of greatest hormonal influence.  
 
 
INTRODUCTION 
Neurofibromatosis type 1 Origin and Loss of Heterozygosity 
 Neurofibromatosis type 1 (NF1) is the most common human cancer predisposition 
syndrome affecting the nervous system, affecting 1/3000 to 1/3500 live births world-
wide. NF1 tumors are heterogeneous, and Schwann Cells (SC) or SC precursors have 
been shown to be the initiating cell type (Serra et al., 2001; Zhu et al., 2002). Loss of 
heterozygosity has been found in some, but not all neurofibromas, and in some but not all 
cell types within the neurofibroma (Menon et al., 1990; Daschner et al., 1997; Rasmussen 
et al., 2000).While neurofibromin is generally a microtubule-associated cytoplasmic 
protein (Gregory et al., 1993), it has also been found to be actively transported to the 
nucleus (Vandenbroucke et al., 2004). 
 The manifestations of NF1 are highly variable, even among members of the same 
family with the same mutation.  However, hallmarks of NF1 include tumors of the 
peripheral nervous system, which are usually benign and often first appear at puberty 
(McLaughlin and Jacks, 2003; Fishbein et al., 2007). Although they are rarely present at 
birth, they are found in 48% of 10 yr olds (notably, precocious puberty is a common 
feature of NF1 (Virdis, 2000)), 84% of 20 year olds, and virtually all NF1 patients over 
the age of 40, (McGaughran et al., 1999; DeBella et al., 2000).  Neurofibromas can also 
arise from multiple nerves within plexuses, which are termed plexiform neurofibromas 
 
 
83 
(Woodruff, 1999; Gutmann and Giovannini, 2002). Plexiform neurofibromas are first 
seen in early childhood and are capable of aggressive growth, particularly as puberty 
approaches or during pregnancy (Dugoff and Sujansky, 1996). About 5% of plexiform 
neurofibromas undergo malignant transformation and eventually become malignant 
peripheral nerve sheath tumors (MPNSTs) (Korf, 1999; Woodruff, 1999). Contributions 
from other mutations, at NF1 or other loci, environmental conditions including trauma 
and the elevated levels of specific hormones seen at puberty and during pregnancy, may 
also be “triggers” for tumorigenesis or enlargement. Such stimuli could be responsible for 
initial growth of the tumors, for increases in tumor size and number during pregnancy, 
puberty or exogenous hormonal stimulation and for malignant transformation (Posma et 
al., 2003). Reports indicate that up to 80% of pregnant women with NF1 experience an 
increase in tumor size and/or number during pregnancy, with one third of these lesions 
regressing in the postpartum period, suggesting a hormonal influence (Dugoff and 
Sujansky, 1996).  
Hormonal Influence on NF1 tumor growth and progression 
 A recent study of 59 NF1 patients who were taking either oral contraceptives or 
who had contraceptive implants, found that only those women with contraceptive 
subdermal implants containing high doses of synthetic progesterone (150 mg 
medroxyprogesterone acetate or 200 mg norethisteron enanthat) experienced an increase 
in the size and numbers of their tumors; those on combined oral contraceptives 
experienced no significant effects on neurofibroma growth (Lammert et al., 2005). 
 
 
84 
 Prospective studies, such as cited above, involved patients with relatively mild 
forms of the disorder whose pregnancies were obstetrically “uneventful” even if there 
were reported increases in the size and number of their neurofibromas (Dugoff and 
Sujansky, 1996).  In contrast, a large number of “retrospective” case studies by 
obstetricians and gynecologists tended to involve only a few women (Ansari and 
Nagamani, 1976), or even single patients, (Posma et al., 2003) and reported severe and 
therefore particularly notable effects. A second pregnancy resulted in one case in the 
overgrowth of a peripheral nerve sheath tumor that had initially arisen during a first 
pregnancy, which proved fatal to the patient in the second pregnancy (Posma et al., 
2003). Another case report found that a patient with initially mild disease symptoms died 
of the results of multiple malignancies, which the physician believed arose and became 
worse during and after pregnancy and delivery (Heffner, 1969; Boiten et al., 1987).  
The Hormonal Milieu During Pregnancy 
 Concentrations of the steroid hormones 17-estradiol (E2), progesterone (P4) and 
testosterone (T) increase during pregnancy (Witorsch, 2002; Fernandez-Valdivia et al., 
2005; Okada et al., 2005; Rodriguez-Cuenca et al., 2006). E2 has been shown to be 
involved in cell proliferation, and is a ligand for the Estrogen Receptor (ER) (Revankar et 
al., 2005). P4 is modified to E2 and is involved in both proliferation and differentiation 
(Fernandez-Valdivia et al., 2005); P4 is the ligand for the Progesterone Receptor (PR) 
(Fernandez-Valdivia et al., 2005). The PR is regulated by E2 by transactivation through 
the ER (Fernandez-Valdivia et al., 2005; Okada et al., 2005). Testosterone is the primary 
circulating androgen, even in women, and is the ligand for the androgen receptor (AR), 
although it can rarely cross-react with both the ER and PR at very low affinity (Gao et al., 
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2005). Steroids can rarely cross-react and bind to receptors other than their native 
receptor, because of the similarity of their receptor conformation, even though the actual 
sequence identity may be low (Gao et al., 2005). Hormone receptor-positive breast cancer 
cells were shown to be more likely to respond to hormone antagonist treatment (Jacobsen 
et al., 2003; Jacobsen et al., 2005). A study done on both male and female neurofibroma 
tumors found 75% expressed PR, while 5% expressed ER, regardless of the sex of the 
patient, although neither co-expression nor expression of AR was tested (McLaughlin and 
Jacks, 2003). Recently, Fishbein et al. found that tumor-derived SC cultures showed 
heterogeneous results for proliferation and apoptosis using steroid hormone ligands and 
receptors. Statistically significant changes applied to only a subset of tumor cells, 
regardless of gender (Fishbein et al., 2007). 
Antimetabolites/Antagonists for Hormones and Angiogenesis 
 2-methoxy-estradiol (2ME2) is a naturally occurring E2 metabolite that rises in 
serum during pregnancy (Wang et al., 2000) and is a potent antiangiogenic factor, 
although it is not ER-dependent (Wang et al., 2000; Dingli et al., 2002). 2ME2 has been 
found to inhibit tumor cells (e.g. breast cancer, prostate cancer, and ovarian carcinoma) 
by destabilizing and depolymerizing microtubules (MT) and impairing hypoxia inducible 
factor 1 (HIF-1) accumulation in the nucleus (Wang et al., 2000; Mabjeesh et al., 2003; 
Ireson et al., 2004). HIF-1 also induces vascular endothelial growth factor (VEGF) 
expression, therefore inhibition of HIF-1 results in inhibition of VEGF expression that is 
required for angiogenesis (Mabjeesh et al., 2003). Tumors require angiogenesis to grow 
larger than 1 mm in size due to the limits of nutrient diffusion to cells, therefore 2ME2 
may be acting indirectly to inhibit tumor growth through inhibition of angiogenesis, 
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although that cannot be the reason 2ME2 has apoptotic effects on cultured tumor cells 
(Wang et al., 2000; Mabjeesh et al., 2003). In such cells, 2ME2 acts by disrupting 
microtubules, with prolonged (24-72 hours) exposure to malignant tumor cells resulting 
in apoptosis (Wang et al., 2000; Mabjeesh et al., 2003).  
An embryonic stem cell-based model of SC differentiation for studies of NF1 
tumorigenesis 
We recently reported a new stem cell based model for studies of tumorigenesis in NF1 
(Roth et al., 2007). This in vitro system has been used to differentiate mouse embryonic 
stem cells (mESC), which are NF1 wild type (+/+), heterozygous (+/-), or null (-/-) into 
Schwann Cell-like cells for studies of NF1 in SC development and tumor formation.  
Regardless of their NF1 status, all of these cells were shown to express SC markers 
appropriate for their maturation stage, including myelin proteins. These stem cell- 
derived SC (mESC) can also preferentially direct neurite outgrowth from primary 
peripheral neurons. We reported that the NF1 -/- and +/- SC-like stem cell-derived cells 
proliferated  more rapidly than NF1 (+/+) cells but that proliferation rates reverted to wild 
type levels after treatment with an inhibitor of MAP kinase kinase (Mek) (Roth et al., 
2007).  We further demonstrated that mESC of all NF1 types could be differentiated into 
neuron-like cells.  This novel stem cell based model system provides an ideal model to 
study of the role of hormones on the cell growth and differentiation of the different cell 
types affected by NF1 in cells with differing levels of neurofibromin that are neither 
transformed nor malignant.  In this study, we have focused on the SC-like cells derived 
from these stem cells.   
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MATERIALS AND METHODS 
Cell Types: The cell lines used for these studies include the NF1+/+ (D3) mES cell line 
(Doetschmann, 1985), NF1+/- (SKO) mES cells (Jacks et al., 1994), NF1-/- (DKO) mES cell  
line (Jacks et al., 1994), SW10 (NF1+/+) mouse Schwann Cell line with a temperature 
sensitive SV40 large T antigen, grown at 37C (the non-permissive temperature for transgene 
expression) for differentiation (ATCC) (Hai et al., 2002), pNF00.11 (referred to as PNF cells 
in this report) (NF1-/-) human plexiform neurofibroma (Muir et al., 2001), ST88-14 (referred 
to as ST cells in this report) (NF1-/-) human MPNST (gift of Dr. Larry Sherman, Oregon 
Health Sciences University) (Su et al., 2004). Positive control cell lines for hormone 
receptors were: ER+ and PR+ MCF-7 cells (gift of Dr. Dorraya El-Ashry, Univ. of MI) and 
AR+ LNCaP cells and mouse breast and prostate tissues (gift of Dr. Diane Robins, Univ. of 
MI).  
Differentiation of mES cells to SC-like cells: We had previously found that mES cells that 
were wild type, heterozygous or homozygous for the NF1 gene could be differentiated into 
neuron-like cells and SC-like cells, (Roth et al., 2007) the latter of which more closely 
approximate the initiating tumor cell type in NF1. SC-like differentiated mES cells will be 
referred to as D3SC (NF1+/+), SKOSC (NF1+/-) and DKOSC (NF1-/-), depending on the 
number of NF1 alleles expressed.  
Media: Proliferating (ES) cells medium consisted of 81% DMEM without Phenol Red, 1% 
L-Glut, 1% Pen/Strep, 1% non-essential amino acids (Gibco, Carlsbad, CA), 15% fetal 
bovine serum (FBS) (Atlanta Biological, Norcross, GA), 1% Sodium Pyruvate(2% stock), 7 
µL/L Mercaptoethanol (Sigma, St. Louis, MO), 1000 U/mL ESGRO (Chemicon, Temecula, 
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CA). Schwann Cell Differentiation (SC) medium consisted of  84% a-mod. MEM without 
Phenol Red, 1% Pen/Strep (Gibco), 10% FBS (Atlanta Biological), 5% 11-day chick embryo 
extract, 10 ng/mL neuregulin NRG-1 (R&D systems, Minneapolis, MN). Tumor cell 
medium for growth of PNF(Muir et al., 2001) and  ST(Su et al., 2004) cell lines contained 
84% DMEM without Phenol Red, 1% Pen/Strep (Gibco), 25 ng/mL NRG-1 (R&D systems), 
15% FBS. SW10 SC cell line medium consisted of 88% DMEM without Phenol Red, 1% L-
Glutamine, 1% Pen/Strep, 10% FBS (Atlanta Biological). Note: Regular FBS was replaced 
by charcoal-stripped FBS (Valley Biomedical, Winchester, VA) in all media used for 
hormone assays. Minimal medium consisted of 87% DMEM without Phenol Red, 10% 
FBS, 1% Pen/Strep, 1% L-Glutamine, 1% Sodium Pyruvate (2% stock). 
Antibodies: All antibodies were diluted in 10% donkey serum (Chemicon International, 
Temecula, CA) in 0.1% Tween20/Phosphate-Buffered Saline (TBST) (Sigma, St. Louis, 
MO). ER (rabbit polyclonal 1:50), AR (rabbit polyclonal 1:50) NF1 (rabbit polyclonal 
1:50) (Santa Cruz, Santa Cruz, CA), Tuj1 (mouse monoclonal 1:500) (Covance, Berkeley, 
CA), Neurofilament (rabbit polyclonal 1:400) (Chemicon International), S100 (rabbit 
polyclonal 1:200 Novocastra, Newcastle Upon Tyne, UK or mouse monoclonal 1:50 Abcam, 
Cambridge, MA), GFAP (mouse monoclonal 1:400) (Chemicon), myelin (mouse monoclonal 
1:10) (Abcam), PR (mouse monoclonal 1:50) (Abcam), tubulin (mouse monoclonal 1:200), 
Caspase-3 (mouse monoclonal 1:1000) (BD Transduction, San Jose, CA), AlexaFluor 350, 
488, 594, DAPI (Molecular Probes, Eugene, OR), goat  rabbit-HRP (Zymed, San Francisco, 
CA). Note: We also looked at ERβ expression, but did not see expression in any of the cells 
or tissues tested. Therefore ER=ERα in this dissertation. Hormones and receptor inhibitors 
used included progesterone, RU486, 17-estradiol, 2ME2 (Sigma) ICI 182,780 (Tocris), 
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testosterone and flutamide (gift of Dr. Diane Robins, University of MI). All were diluted in 
100% ethanol, which was also used for vehicle wells. Reagents used included CellTiter96 
cell proliferation assay kit (Promega), Histomouse (Zymed), Prolong Gold anti-fade 
(Molecular Probes), Porcine gel (Sigma), In situ cell death detection kit, fluorescein 
(TUNEL) (Roche, Indianapolis, IN), Citrisolv, Ethanol, Sodium citrate dihydrate  (Fisher 
Scientific, Fair Lawn NJ).  
Immunocytochemistry (ICC): On day 0, 40,000 cells were plated onto 0.1% porcine gel-
coated coverslips (Corning, Corning, NY) and grown overnight. For microtubule 
visualization in the 2ME2 assay, varying concentrations of 2ME2 were added to the media; 
cells were grown an additional 24 hours. Cells were then fixed in 4% paraformaldehyde 
(Sigma), permeabilized in 0.2% TritinX100 (Sigma), stained and mounted on Superfrost plus 
slides (Fisher, Pittsburgh, PA). Fluorescence micrographs photographs were taken with an 
Olympus BX-51 microscope, and non-fluorescent micrographs with Nikon ACT-1 software 
on a Leitz Diavert inverted microscope. 
Hormone Receptor Immunohistochemistry (IHC) on mouse tissue: The control mouse 
tissues used in this study were from a pool of phenotypically indistinguishable mice with four 
genotypes: NF1flox/+;P0A-cre+, NF1flox/flox;P0A-cre-, NF1flox/-;P0A-Cre-, and NF1+/-. 
The mutant mice used were of the genotype, NF1flox/-;P0A-cre+ (mutants). Twelve to 
twenty months old mice were monitored until signs of distress appeared, at which time they 
were subjected to necropsy.  The P0A-cre transgenic strain was initially generated on the 
FVB background (Giovannini et al., 2000). After five generations of being backcrossed to the 
129 Svj background, the P0A-cre transgenic mice were crossed to the NF1flox/- mice that 
were maintained on the 129 Svj background. Subsequent crosses generated control and 
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mutant mice for analysis (Zhu et al, 2002, Zheng et al, submitted). All mice in this study 
were cared for according to the guidelines that were approved by the Animal Care and Use 
Committees of the University of Michigan at Ann Arbor. For histological analysis, control 
and mutant littermates at 12-22 months of age were perfused with 4% paraformaldehyde 
(PFA).  Sciatic nerves were dissected, post-fixed overnight for 2 hours at room temperature 
and transferred to 30% sucrose overnight. Sciatic nerves were embedded using OCT medium 
and sectioned longitudinally at 65 m thicknesses using a cryostat. Mouse tissue slides were 
deparaffinized in Citrisolv and rehydrated in successive dilutions of ethanol. Antigen 
retrieval was performed by boiling slides for 10 min. in 0.01M sodium citrate buffer pH 6.0, 
followed by IHC at room temperature in a humidified chamber. Non-specific binding was 
blocked with 10% donkey serum, incubated with primary antibodies listed followed by 
secondary antibody incubation for 20 minutes and 5 minute DAPI staining. Washes between 
steps were done in 0.1% PBST.  After coverslips were applied using Prolong Gold anti-fade 
mounting medium and dried in the dark overnight, photographs were taken at 40x 
magnification using an Olympus BX-51 microscope. 
Measures of Cell Proliferation: A) Hormones and receptor inhibitors: Cells were grown 
overnight in hormone-free phenol red-free media. The next day, cells were counted, plated 
and allowed to attach for two hours in SC differentiation medium (containing hormone 
receptor inhibitor if specified) before hormone was added in the concentrations indicated. 
Inhibitors and hormones were replenished after 48 hours. At four days growth, proliferation 
was assayed using a Beckman Z1 Particle Coulter counter (Beckman Coulter, Inc., Fullerton, 
CA).  Cell numbers were converted to percentages using proliferation of cells in ethanol-
containing (vehicle) wells as 100%. Statistical analysis: data are expressed as mean +/- SD, 
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and the Student’s t-test was used to gauge significance, which was (p<0.05). B) 2ME2: Cells 
were counted, plated, and allowed to attach overnight in hormone-free medium and phenol-
red free medium. Varying concentrations of 2ME2 were added to the media; cells were 
grown an additional two days, proliferation was assayed using the CellTiter96 (Promega) 
proliferation assay and absorbance was measured by microplate reader (Fisher).  Absorbance 
was converted to percentages using absorbance of cells grown in vehicle (EtOH) as 100%. 
Equation used: treated well/vehicle well x 100.  
RTqPCR: RTqPCR was performed using primer pairs designed using the Beacon designer  
program (BioRad, Hercules, CA), target with Ta at 55º C, a length 18-22 bp and amplicon 
size 100 – 200. Gene expression was normalized to GAPDH. Total RNA from the samples 
was extracted using a Qiagen RNeasy Kit (Kit 74106, Qiagen, CA). RT-PCR was performed 
as follows: cDNA was synthesized from 2 µg total RNA by reverse transcription using Super 
Script III transcriptase (Invitrogen, Carlsbad, CA) and oligo dT primer. A 2 µL aliquot of the 
cDNA of each sample was used for PCR with the hormone receptor primers. The PCR 
conditions included an initial denaturation at 94C for 1min, followed by 94C for 1 min, 
55C for 30 sec and 74C for 30 sec and 34 cycles and final extension at 72C for 5 min with 
a 4C holding temperature. The PCR products were separated on 2.0% agarose gels and 
visualized using ethidium bromide under UV light.  
PCR primers: NF1: forward AGTTTCTCTCCTCGCTGGTCTTC reverse 
CGTTTCCTGCCACCCGTTTG; AR: Forward: GCGGTCCTTCACTAATGTCAACTC 
Reverse: TGCCTCATCCTCACACACTGG; PR: Forward: 
CTGGATGAGCCTGATGGTGTTTG Reverse: GGCACAGCGAGTAGAATGACAG; ER 
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Forward: GAAAGGCGGCATACGGAAAGAC Reverse: 
TCAAGGACAAGGCAGGGCTATTC. 
TUNEL assay: Apoptosis was measured by TUNEL assay. PNF and ST cells were plated, 
grown, fixed and permeabilized as in the 2ME2 ICC assay. The TUNEL assay was 
performed according to Roche kit specifications with the following modifications. Caspase-3 
antibody was added at 1:1000 to the TUNEL reaction mixture and incubated at 37C for 60 
minutes in the dark. After PBS rinses, DAPI was added at 1:1000 for 3 minutes. Coverslips 
were mounted on slides with Molecular Probes’ Antifade medium and dried 24 hours in the 
dark before fluorescence visualization. 
 
RESULTS  
The expression of steroid hormone receptors is correlated with NF1 expression in SC-
like mES-derived cells 
 To determine whether the mES-derived SC-like cells or human SC tumor cell lines 
responded differently to the steroid hormones that are upregulated during pregnancy (P4, E2, 
and T), we first determined whether these cells expressed the appropriate receptors (PR, ER, 
AR) for the relevant classical steroid receptor pathways. We found that the level of classical 
receptor expression varied depending on the level of neurofibromin expressed by the cell 
type/line. While PR (figure 3.1A, first column) was not intensely expressed in any of the cell 
lines, the NF1-/- (DKOSC, PNF, ST) cells had the most intense staining, although the 
Schwann cell line SW10 also showed some PR expression (figure 3.1A, bottom row, left).  
ER expression (figure 3.1A, third column) and AR expression (figure 3.1A, fifth column) 
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followed similar patterns to each other, with little/no expression in the NF1+/+ (D3SC, 
SW10) cells, low levels of expression in NF1+/- (SKOSC) cells, and more intense levels of 
expression in NF1-/- (DKOSC, PNF, ST) cells. While PR and AR expression was nuclear, 
ER localization was seen in both the nucleus and the cytoplasm, as has been previously noted 
(Ho and Liao 2002; Revankar et al. 2005; Zhang et al. 2004). The differences in expression 
levels were confirmed in mouse SC-like cells by RTqPCR (figure3.1B). In RTqPCR 
assessments, D3SC cells expressed 20% of the amount of PR, 0.5% of the ER and 9.4% of 
the AR seen in DKOSC cells (set at 100%), while SKOSC cells expressed 24% of the 
amount of PR, 0.25% of the ER and 41.6% of the AR expressed by DKOSC cells (figure 
3.1C). We then co-stained for both steroid hormone receptors and SC markers in the same 
cells in order to verify co-expression levels (figure 3.2A-C).  
 In order to assay whether in vivo mouse tissue with or without NF1 expression show 
similar patterns of classical hormone receptor expression as mouse cells in vitro did, we 
obtained tissue from mice in which cre transgene targeted the loss of NF1 in cells only from 
the Schwann Cell lineage and stained for classical hormone receptor expression. Mice which 
carried the cre transgene (cre+) developed hyperplasia in trigeminal nerves and neurofibroma 
tumors in dorsal root ganglia (DRG) (figure 3.3). High levels of ER (green, middle columns) 
and AR (green, right columns) were seen in NF1-deficient mouse tissues (cre+), but not in 
mouse tissue with normal NF1 expression levels (cre-), similar to the expression patterns 
seen in cultured mouse cells (figure 3.3). In contrast to the in vitro assays, however, high 
levels of PR (red, left columns) expression were also seen in NF1-deficient mouse tissues 
(cre+) (figure 3.3).  
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Hormonal Effects on Cell Proliferation 
 Because expression of hormone receptors was found to be associated with the level of 
NF1 expression in the cells tested, with DKOSC cells expressing much more intense levels 
of the receptors than either the D3SC or SKOSC cells (figure 3.1B, figure 3.2A-C), we 
assayed the cells for hormonal effects on cell proliferation. Concentrations of the hormones 
were chosen based on dose response curves that determined the optimal doses that induced 
proliferation rather than differentiation (not shown). After growing the cells overnight in 
hormone-free phenol-red free media, we added one of the ligands for the steroid hormone 
receptors (P4, E2, and T) and/or its respective nuclear receptor inhibitor (RU486, ICI 182, 
780 or Flutamide) (Wang et al., 2000; Witorsch, 2002) (figure 3.4). Addition of P4 (figure 
3.4A) increased proliferation significantly only in SW10, ST and DKOSC cells. The effect of 
the PR inhibitor RU486 was cell type-specific, ranging from significant inhibition even 
below control levels (SW10 and PNF) to no significant effect (ST, D3SC, SKOSC, DKOSC) 
(figure 3.4A) n=5. Addition of E2 (figure 3.4B) or T (figure 3.4C) significantly increased 
proliferation of malignant NF1 tumor cells (ST) and DKOSC and D3SC cells. However, the 
NF1-/- cell lines ST and DKOSC cells were the only cell lines that showed a significant 
increase in proliferation with all three of the hormones tested. There was generally a slight 
trend, although not a significant decrease, seen when their respective inhibitors for the 
classical receptors (ICI 182, 780 for ER, Flutamide for AR) were used to preincubate cells 
for 2 hours.  
 
 
 
 
95 
2-Methoxy-estradiol (2ME2) effects 
 In order to determine whether 2ME2, an estrogen metabolite that has been found to be 
upregulated during normal pregnancies (Wang et al., 2000), affected the growth of NF1-/- 
mES cells, we grew the SC-like mES cells, SW10 and the tumor cell lines for 3 days in 
2ME2 concentrations between 0.1 µM and 100 µM. We determined that 10 µM was the 
threshold for significant changes in growth rates in all cells and cell lines tested (not shown). 
To determine if the effect was cytotoxic (causing apoptosis) or only to decrease proliferation, 
we grew all cells for two days in 10 µM 2ME2. Malignant ST cells were the only cell type to 
show a significant decrease in cell number when compared to the initial cell number (figure 
3.5A). All other cells had either static cell numbers (PNF, DKOSC, and D3SC), or merely 
decreased proliferation rates (SKOSC, SW10) compared to control cells grown without 
2ME2 addition.  
Effects of 2ME2 Exposure on Microtubules 
 The mechanism of 2ME2 action in cultured cells is reported to be through disruption of 
microtubules (Mabjeesh et al., 2003), and not through effects on the classical ER itself, for 
which it has very low affinity (Ireson et al., 2004). We therefore examined tumor cells grown 
with or without added 2ME2 for expression of tubulin to visualize any changes in these 
cytoskeletal elements with increasing concentrations of 2ME2. We found that with the 
addition of 10 µM 2ME2 (figure 3.5B, middle column), the PNF cells rounded up but their 
nuclei (stained with DAPI) remained intact and the cells retained some cytoskeletal structure. 
In the ST cells, however, cells appeared to have the classic apoptotic profile (Edinger and 
Thompson, 2004). The cells rounded up, nuclei were “broken up” and appeared as clusters of 
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nucleic acid-containing material, and cell membranes were blebbed (Edinger and Thompson, 
2004). The microtubules no longer were found in long extensions (figure 3.5B, left column), 
and tubulin protein was more diffuse in the cytoplasm. With 100 µM 2ME2 (figure 3.5B, 
right column), PNF cells also began to lose microtubule extensions, tubulin expression was 
diffuse, and 5-10% nuclei were becoming clustered and fragmented. ST cells became 
reduced in size (less than half the normal diameter) and apoptotic, with very little cytoplasm 
extending beyond the nucleus, thus visually exhibiting a much stronger effect from the 2ME2 
on the cytoskeleton. To confirm that these malignant ST cells were becoming apoptotic in 
2ME2, we assayed them for both caspase-3 expression and TUNEL staining. While less than 
1% of benign PNF tumor cells were TUNEL+ and Caspase-3+, approximately 20% of ST 
cells stained positive for these apoptotic markers after 24 hours (figure 3.5C).  
 
DISCUSSION 
 Because NF1 tumors often grow in size and increase in number during pregnancy 
(Ansari and Nagamani, 1976; Dugoff and Sujansky, 1996), suggesting a hormonal 
influence, we conducted experiments to determine whether the mES-derived SC-like 
cells or human SC tumor cell lines with variable levels of neurofibromin responded 
differently to the steroid hormones that are upregulated during pregnancy (P4, E2, and T) 
(Fernandez-Valdivia et al., 2005; Okada et al., 2005; Rodriguez-Cuenca et al., 2006). We 
first determined that these cells expressed the appropriate receptors (PR, ER, AR) for the 
relevant classical steroid receptor pathways (Chen et al., 2005; Okada et al., 2005; 
Ozawa, 2005; Sonneveld et al., 2006). We found that the level of receptor expression 
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varied depending on whether the cell type/line expressed neurofibromin and at what 
levels. NF1-/- (DKOSC, PNF, ST) cells had the most intense levels of PR expression, 
while ER and AR expression followed similar patterns to each other, with very low/no 
expression in the NF1+/+ (D3SC, SW10) cells, low levels of expression in NF1+/- 
(SKOSC) cells, and most intense expression in NF1-/- (DKOSC, PNF, ST) cells. The 
differences in expression levels were confirmed in the mouse SC-like cells by RTqPCR. 
These findings suggest that NF1 mutant cells can more readily respond to hormones that 
rise during pregnancy. Since at least a part of this increase is inhibited by the classical 
receptor inhibitors, some of this increase can be attributed to these classical pathways. 
Other possible non-genomic pathways include second messenger cascades involving G-
protein coupling, cAMP and MAPK pathway activation that affects Ca
++
 channels, and 
PI3K and Akt pathways (Zhang et al., 2004). PR and AR localization was exclusively 
nuclear, and ER was seen in both the nucleus and the cytoplasm, in accord with the 
findings of others (Ho and Liao 2002; Revankar et al. 2005; Zhang et al. 2004). Breast 
cancer tumor cells that express both ER and PR have been found to have a better 
prognosis because they are more likely to respond to hormone antagonist treatment 
(Jacobsen et al., 2003), although tumors that express only ER or PR, but not both, have 
been reported to have a poorer outcome (Jacobsen et al., 2005). McLaughlin and Jacks 
(2003) suggest an important role of P4 in tumor development regardless of the patient’s 
sex; however, tumor cell type was not identified and tumors were not tested for co-
expression of ER and PR; AR expression was not tested or not reported in their study. 
Positive expression of tumors was defined in their study as slides with 5 or more positive 
cells per 10 high power fields, with virtually none of the sections containing more than 
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one hundred positive cells (McLaughlin and Jacks, 2003). We assayed for in vivo 
expression of classical hormone receptors (PR, ER, AR) in mouse tissues engineered to 
target loss of NF1 in Schwann Cell lineage cells carrying a cre transgene (Zhu et al., 
2002, Zheng et al. submitted), which subsequently developed hyperplasias (trigeminal 
nerve) or neurofibroma tumors (dorsal root ganglia). We found high levels of expression 
of all three classical receptors (ER, AR, PR) in NF1-deficient tissues (cre+), and low/no 
expression in tissues with normal levels of NF1 expression (cre-). This is in contrast to 
our in vitro findings, where ER and AR were upregulated in NF1-/- cells, but PR was not. 
We attribute this difference to the importance of the microenvironment in tumorigenesis, 
since surrounding cells and their resultant signals with and in addition to the NF1-
deficient cells could also be affecting hormone receptor expression. Fishbein et al. found 
differing heterogeneous levels of ER, PR and AR in most NF1 tumor samples and normal 
SCs tested. Primary tissue samples they tested showed higher variation than cultured 
samples, implying that cells other than SC express hormone receptors (Fishbein et al., 
2007). Our results indicate that E2 is likely also to be an important hormone, although its 
effects may be enhanced or influenced by P4. Since T is a precursor for E2, proliferative 
effects on cells could be mediated through aromatase activity (Gao et al., 2005), or 
through non-classical indirect pathways by increasing intracellular Ca
++
 (Chen et al., 
2005), rather than through the AR itself. For example, anabolic effects of androgens in 
muscle may be mediated through insulin-like growth factor-1, perhaps through 
upregulation of IGF receptors. Androgens can also oppose the action of glucocorticoids 
or have a dominant negative effect on glucocorticoid receptors (GR) either by 
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downregulating GR or competing for GR binding, and glucocorticoids can also bind to 
the AR (Chen et al., 2005).   
 Expression of hormone receptors was found to be associated with the level of 
NF1 expression in the cells tested in the stem cell model of SC differentiation, with NF1-
/- (DKOSC) SC-like cells expressing much higher levels (up to 400x) of the receptors 
than either the NF1+/+ (D3SC) or NF1+/- (SKOSC) SC-like cells. We therefore assayed 
the cells for hormonal effects on cell proliferation. Concentrations were chosen based on 
dose response curves that determined the optimal proliferation response vs. 
differentiation (not shown). Although the increases in proliferation we found were 
modest, they were significant. Addition of P4 (figure 3.4A) increased proliferation 
significantly only in SW10, ST and DKOSC cells, possibly because P4 can also be 
involved in cell differentiation and modulation of E2 proliferative effects (Jacobsen et al., 
2003). E2 and P4 can have complementary functions, with P4 inhibiting the ER 
(Jacobsen et al., 2003). P4 and E2 can be used in combination to stimulate tumor 
development by simulating pregnancy in mice with dormant mammary tumors (Gattelli 
et al., 2004), where the combination of E2 and P4 caused the tumor cells to break 
dormancy and begin proliferating. P4 may need to be tested in combination with E2 to 
see a synergistic effect on proliferation, although we first wanted to determine each 
hormone’s effect individually. Also, PR had the least expression of any of the receptors 
we tested in any of the SC-like mES cells with variable neurofibromin levels or in the 
tumor cell lines, even though it had previously been found that 75% of neurofibromas 
tested expressed PR and 5% expressed ER (McLaughlin and Jacks, 2003). Perhaps this is 
because here we are testing cell lines, rather than the cellularly heterogeneous tumors 
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assayed in the McLaughlin and Jacks paper. McLaughlin and Jacks also did not assay for 
the number of receptors per cell, but just the presence of PR and ER in neurofibromas. 
We found that the effect of the PR inhibitor RU486 was variable, ranging from 
significant inhibition of cell proliferation even below control levels in some cell types 
(SW10 and PNF) to no significant effect (ST, D3SC, SKOSC, DKOSC). RU486 is also 
an inhibitor of AR and GR that could also influence the results, although since these cells 
were grown in hormone-free media with only P4 added, this influence should be 
minimized. Addition of E2 or T significantly increased proliferation of malignant NF1 
tumor cells (ST) and DKOSC and D3SC cells. However, the NF1-/- cell line ST, derived 
from the human malignant tumor and the mES-derived NF1-/- (DKOSC) SC-like cells 
were the only cell lines that showed a significant increase in proliferation with all three of 
the hormones tested. There was generally a slight trend, although not a significant 
decrease in proliferation when their respective inhibitors (ICI 182, 780 for ER, Flutamide 
for AR) were used to preincubate cells for 2 hours. This may be because the hormone 
action is not mediated exclusively through classical pathways (McEwen and Alves, 1999; 
Ho and Liao, 2002; Zhang et al., 2004; Chen et al., 2005; Gao et al., 2005; Jacobsen et 
al., 2005; Revankar et al., 2005; Sonneveld et al., 2006). There have been reports of 
steroid hormones (P4, E2, T) influencing cells independent of their classical receptors 
(PR, ER, AR) (McEwen and Alves, 1999; Ho and Liao, 2002; Zhang et al., 2004; Chen et 
al., 2005; Gao et al., 2005; Jacobsen et al., 2005; Revankar et al., 2005; Sonneveld et al., 
2006). E2 has also been shown to modulate secondary messengers, such as Ca
++
 and NO, 
and activate the PI3K/Akt and MAPK pathways (McEwen and Alves, 1999; Ho and 
Liao, 2002; Revankar et al., 2005). These effects are not inhibited by ER inhibitors, 
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suggesting they are not mediated through the classical receptors (Ho and Liao, 2002). 
Many of the E2-stimulated pathways are initiated at the plasma membrane, suggesting 
that they could be mediated by an unidentified G-protein coupled receptor (Ho and Liao, 
2002). Nongenomic actions of androgen with plasma membrane-associated signalling 
pathways involve activation of kinase signalling cascades or modulation of intracellular 
Ca
++
 thought to be mediated through interaction of AR and cytosolic pathway proteins 
(Gao et al., 2005). Conversely, steroid receptors have been shown to exert their influence 
without hormone stimulation (Chen et al., 2005; Jacobsen et al., 2005; Sonneveld et al., 
2006). Genes regulated by unliganded PR encode membrane associated, cell-cycle 
regulatory, DNA repair and apoptosis proteins (Jacobsen et al., 2005). ER has been 
found to activate the PI3K/Akt pathway in an E2-independent manner by binding 
constitutively to the p85 subunit of PI3K and activating PI3K/Akt pathway (McEwen and 
Alves, 1999; Ho and Liao, 2002). ER expression has been seen outside the nucleus 
(McEwen and Alves, 1999; Ho and Liao, 2002; Zhang et al., 2004; Revankar et al., 
2005), for example, ER localized to the cytoplasm and plasma membrane of neurons 
and astrocytes, and was also seen in the myelin of oligodendrocytes and glia (Zhang et 
al., 2004). PR also regulates a cluster of G-protein signalling pathways, ras and multiple 
kinase pathways (Jacobsen et al., 2003). 
 We also hypothesize that the complex hormonal milieu during pregnancy or the 
response to these hormones may be different in women with NF1. For example, 2-
methoxy-estradiol (2ME2), which is an estrogen metabolite, has been found to be 
upregulated during pregnancy (Wang et al., 2000). We hypothesize that 2ME2 may either 
be present at lower levels systemically in women with NF1, resulting in tumor 
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overgrowth, or cell receptors for 2ME2 may be lacking in NF1-/- cells. 2ME2 has been 
found to be cytotoxic to numerous tumor cells as well as some other rapidly-growing 
cells (Mabjeesh et al., 2003), but not to normal or quiescent cells, by inducing apoptosis 
(Wang et al., 2000; Ireson et al., 2004).  Wang et al. (Wang et al., 2000) found that 
normal thyroid cells first underwent cell cycle arrest with apoptosis initiated after 
prolonged (6 days) exposure. 2ME2 has no E2-like activity and has very low affinity for 
the ER; suggesting it is not ER-dependent (Wang et al., 2000; Ireson et al., 2004). The 
mechanism of 2ME2 action is reported to be through disruption of microtubules by 
destabilization and disassembly, and impairment of  hypoxia inducible factor-1 (HIF-1) 
nuclear accumulation, thus inhibiting vascular endothelial growth factor (VEGF) 
expression (Mabjeesh et al., 2003). VEGF is required for angiogenesis, which in turn is 
needed for tumor growth beyond the size at which nutrients can diffuse. In vitro, 2ME2 
competes with colchicine for tubulin binding sites and disrupts interphase microtubules, 
resulting in cell death (Mabjeesh et al., 2003). Neurofibromin has been found to associate 
and co-purify with microtubules, suggesting NF1 involvement in microtubule-mediated 
pathways (Gregory et al., 1993). We determined that 10 µM was the threshold for 
significant changes in growth rates in all cells and cell lines tested (not shown). We found 
that 2ME2, a naturally occurring estrogen metabolite, disrupts microtubules and is 
cytotoxic to malignant NF1 tumor cells while its effect is to slow or halt the growth of the 
other cell lines tested, regardless of their NF1 status. This suggests that perhaps 
additional mutations, for example p53, which has been associated with MPNSTs (Menon 
et al., 1990), are needed for 2ME2 cytotoxic effects specific to malignant tumors, since 
non-malignant NF1 tumor cells did not undergo apoptosis with 2ME2 treatment.  
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 Future studies will focus on the effects of these hormones separately and in 
combination, on these stem cell derived SC-like cell lines and other cells whose NF1 
status is known, including other malignant NF1 tumor cell lines. Because of the complex 
hormonal milieu during pregnancy, it will be necessary to look for synergy among 
hormone effects. We will also investigate the mechanisms of these hormones’ effects 
through other mechanisms than their classical receptors. We also hypothesize that the 
effect of hormones on neurofibromas may be indirect through hormonal effect on 
angiogenesis. Increased blood vessel formation during pregnancy could allow existing 
tumors to grow, as well as increase microscopic tumors to grow to detectable sizes. It is 
also worth noting that while most of the cultured cells in this study are mouse cells, the 
tumor cell cultures are from human neurofibromas, which may explain some of the 
differing results. 
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Figure 3.1: A: SC-like cells and NF1 tumor cells express varying levels of steroid 
hormone receptors. DAPI staining of cell nuclei is shown to the right of the hormone 
receptor assayed. Left column, PR: Low levels of PR expression were seen in all cell 
types, with some upregulation in NF1-/- (DKOSC, PNF, ST) cells. Third column, ER and 
fifth column AR: Very low levels of both ER and AR seen in NF1+/+ (D3SC, SW10) 
cells, a slightly higher level in NF1+/- (SKOSC) cells, and most intense levels in NF1-/- 
(DKOSC, PNF, ST) cells suggests a stronger ability of NF1-/- cells to respond to 
hormones upregulated during pregnancy. Some cell types displayed both nuclear and 
cytoplasmic expression of ER. Photographs were taken at 40x magnification. B: Using 
gel visualization, expression of hormone receptors was verified by RTPCR (D3=D3SC, 
SK=SKOSC, DK=DKOSC). C: RTqPCR shows percentage of hormone receptor 
expression of D3SC and SKOSC cells in comparison to DKOSC cells (DKOSC 
expression set at 100%). D3SC cells expressed 20% the amount of PR, 0.5% ER and 
9.4% PR of DKOSC cells, while SKOSC cells expressed 24% the amount of PR, 0.25 ER 
and 41.6% AR of DKOSC cells.  
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Figure 3.2: Co-expression levels of steroid hormones and SC markers in SC-like 
differentiated mES cells. This verifies the co-expression levels of S100 and PR, GFAP 
and ER or S100 and AR in A: D3SC cells B: SKOSC cells and C: DKOSC cells. The 
staining for all three hormone receptors (PR, ER, AR) was most intense in the DKOSC 
(NF1-/-) cells (C), while all three cell types (D3 NF1+/+, SKOSC NF1+/-, and DKOSC 
NF1-/-) expressed the SC markers, S100 or GFAP. Photographs were taken at 40x 
magnification.
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Figure 3.3: Hormone receptor expression in mouse tissue. In order to assay for classical 
hormone receptor expression in vivo, we obtained mice in which cre recombinase 
expression targets loss of floxed NF1 expression to cells in the Schwann Cell lineage 
(Zhu et al., 2002, Zheng et al., submitted). Mice transgenic for the cre transgene 
developed hyperplasia in the trigeminal nerve and neurofibroma tumors in dorsal root 
ganglia (DRG), while mice without the cre transgene expressing normal NF1 levels did 
not.  In vivo, mouse tissues with or without NF1 expression showed similar patterns of 
classical ER (green, middle columns) and AR (green, right columns) steroid hormone 
receptor expression as mouse cells in vitro. The NF1-deficient tissues (cre+) had intense 
expression of ER and AR, while the NF1+ (cre-) did not. PR expression (red, left 
columns), however, was much more robust in NF1-deficient tissues (cre+) than that seen 
in cultured NF1-/- cells. This could be attributed to signaling from the  surrounding cells 
in the tumor tissue micrownvironment, in contrast to the homogeneous NF1-/- cells in 
culture. DAPI staining of cell nuclei is shown in blue. Micrographs were taken at 40x 
magnification. 
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Figure 3.4: Hormones that are increased during pregnancy affect the proliferation of SC-
like cells and NF1 tumor cells differently, depending on the level of neurofibromin 
expression. P4: Addition of 0.1 µM P4 increased proliferation significantly only in 
SW10, ST and DKOSC (asterisk), while 1.0 µM PR inhibitor RU486 returned 
proliferation rates to control levels (plus sign). E2: 0.1 µM E2 increased proliferation 
significantly in malignant NF1 tumor cells (ST), DKOSC, and D3SC cells (asterisk), 
while addition of 1.0µM ER inhibitor ICI 182, 780 reduced proliferation rates to control 
levels only in D3SC cells, which had a small but significant difference (plus sign). T: 
Addition of 1.0 µM T also significantly increased proliferation only in malignant NF1 
tumor cells (ST), DKOSC and D3SC SC-like differentiated mES cells (asterisk); addition 
of 10 µM of the AR inhibitor Flutamide returned proliferation rates to control levels (plus 
sign). 
 
 
111 
 
 
112 
Figure 3.5: 2ME2, a naturally occurring E2 metabolite, is cytotoxic to a malignant NF1 
tumor cell line, but only slows or halts growth in other cell lines tested. Microtubules are 
disrupted in this process. A: When cells were grown for 2 days in 10 M 2ME2, 
malignant ST cells were the only cells that showed significant cell death compared to 
beginning cell numbers. All other lines (including the benign PNF tumor cells) either had 
static numbers (PNF, DKODC, D3SC), perhaps due to cell cycle arrest, or merely 
decreased proliferation (SKOSC, SW10) B: Tumor cells were plated and attached 
overnight before the listed concentration (0 M left, 10 M middle, 100 M right) was 
added to the media. After an additional 24 hours incubation, cells were fixed and stained 
for α-tubulin (microtubules), S100 (SC origin of cells) and DAPI (nucleus), 40x 
magnification. Tumor cells grown without 2ME2 (left) had extensive tubulin networks. 
Addition of either 10 M (middle) or 100 M (right) 2ME2, however, caused the cells to 
round up and appear apoptotic-nuclei were breaking up and appeared as clusters, and the 
cells showed blebbing. The microtubules no longer stained as strands, but tubulin showed 
a more diffuse expression.  All of these effects were more pronounced in the malignant 
ST cells, which showed very little cytoplasm beyond the nucleus in the presence of 10 
M or 100 M 2ME2. C: Tumor cells were grown as described and stained for TUNEL 
and caspase-3 expression. While approximately 20% of the malignant ST cells (bottom 
row) were positive for apoptosis, only about 1% of the benign PNF cells were positive 
(top row).  
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CHAPTER IV 
 
CONCLUSION 
 Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder of the nervous 
system, resulting in neurofibromas of the peripheral nervous system (Friedman et al., 
1999; Roth et al., 2007a). These mostly benign tumors are thought to originate from 
Schwann Cells (SC) and their precursors (SCP) (Zhu et al., 2002; Parada et al., 2005), 
and tend to increase in size and number at puberty and pregnancy (Posma et al., 2003; 
Virdis et al., 2003), suggesting hormonal influences. Neurofibromas contain a 
heterogeneous population of cell types, including SC, SCP, neurons, fibroblasts, and mast 
cells (Gutmann et al., 1994; Blum and Kambich, 1997; Feldkamp et al., 1998; Friedman 
et al., 1999). 
 While mast cells are commonly seen upregulated in response to tissue 
inflammation (Galli and Wershil, 1996; Theoharis and Conti, 2004; Marone et al., 2002), 
they are also found in other tumors, such as mammary adenocarcinomas and melanoma 
(Theoharis and Conti, 2004). The presence of mast cells in neurofibromas is perivascular 
in close proximity to neurons, and NF1 has been shown to modulate mast cell growth 
(Theoharis and Conti, 2004, Ingram et al., 2000).There also appear to be functional 
connections in interactions between nerve endings and mast cells when grown in co-
culture (Marone et al., 2002).  
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 The cell types found in NF1 tumors of both the benign and malignant types are 
heterogeneous and LOH is variable even among a specific cell type contributing to the 
tumors. Furthermore, although increases have been found in both size of tumors and 
numbers of tumors (or enlargement of microscopic tumors to visible size) during times of 
puberty and pregnancy, times at which hormones may be playing a role, a rigorous 
examination of the effects of hormones on cells with and without neurofibromin has been 
difficult. Such studies require a homogeneous population of cells of a given cell type that 
have the same known NF1 status. This dissertation provides the first study of which we 
are aware that has devised an in vitro system of differentiating mouse embryonic stem 
(mES) cells of known NF1 status preferentially into Schwann Cell-like (SC-like) cells or 
other cell types affected in NF1. The SC-like cells derived from mES cells, regardless of 
NF1 status, express appropriate SC genes in the expected order of expression for SC 
maturation, support and preferentially direct primary ganglion neurite outgrowth, and 
express myelin in cells near neurites (Roth et al., 2007b). 
 mES cells provide a good model system for studying NF1 because they represent 
a homogenous population of clonally-derived cells that are available in all NF1 genotypes 
+/+, +/-, -/- (representing LOH), contain a known mutation site (Jacks et al., 1994) and 
are neither transformed nor malignant. Also, NF1 tumors are initiated from SC/SCP cells 
and the mES cells can be differentiated into cell types all along the SC pathway from ES 
 neural crest SCP  immature SC  mature myelinating or non-myelinating SC. 
These differentiated cells of known NF1 status can then be used both in vitro and in vivo 
to test effects of hormones, hormone metabolites or other compounds on proliferation, 
tumor formation and growth, differentiation, apoptosis, and cell functions. Other cell 
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types found in neurofibromas, such as neurons, can also be differentiated from mES cells 
of all NF1 genotypes and studied in contrast to or in combination with SC-like cells 
(Roth et al., 2007b; Roth et al., 2007c).  
 In contrast to in vivo studies, where tumor phenotypes are only seen after NF1 
LOH, we found several phenotypic responses in the NF1+/- (SKOSC) SC-like cells as 
well as NF1-/- (DKOSC) SC-like cells as compared to the NF1+/+ (D3SC) SC-like cells. 
Our hypothesis is that this is due to the homogeneous in vitro culture system, without 
signals from surrounding NF1+/- cells and other micro-environmental factors. These 
surrounding signals could rescue in vivo tissues from displaying an NF1 haplo-
insufficient phenotype. In our studies, all of the SC-like cells, regardless of NF1 
genotype, were morphologically similar to SC, expressed SC protein markers S100 and 
GFAP, and supported neurite outgrowth.  We also noticed some differences in the SC-
like differentiated cells. We found that both NF1+/- and NF1-/- SC-like cells were over-
proliferative in culture, even in the presence of primary neurons. This overproliferation in 
both NF1+/- and NF1-/- cells could be reduced to normal levels with the addition of a 
Mek inhibitor, indirectly suggesting Ras pathway involvement.   
 In vitro, all mES cell lines, regardless of NF1 genotype, recapitulated the 
progression of cell types all along the SC pathway from ES  neural crest SCP  
immature SC. In contrast, we found that NF1+/+ SC-like cells (D3SC) are more likely to 
express myelinating SC genes, become quiescent in the presence of SAG neurites and 
associate with SAG neurites similarly to SW10 mouse SC. NF1+/- (SKOSC) and NF1-/- 
(DKOSC) SC-like cells are more likely to stimulate greater neuron migration, neurite 
outgrowth and branching, express non-myelinating genes, slightly reduce proliferation in 
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the presence of SAG neurites and do not associate properly with SAG neurites. In 
addition to overproliferation, this result could be a proximity issue, since there is a 
reduced need for the close proximity of neurons to SC in vitro compared to the close 
quarters of in vivo neuron/SC interaction. We would also like to see what effects, if any, 
are seen on neurite/SC interaction if Mek is over-stimulated in the SC-like cells. 
Overproliferation of NF1 deficient (SKOSC) and null (DKOSC) SC-like cells can be 
reduced to NF+/+ (D3SC) levels by the addition of a Mek inhibitor, indirectly indicating 
Ras pathway involvement (Roth et al., 2007b). In order to more directly assay Ras 
pathway involvement, we would need to look at the effects on Mek phosphorylation 
when U0126 (Mek inhibitor) is added.  
 In studies of classical steroid hormone pathways, we found that SC-differentiated 
NF1-/- cells (DKOSC) and NF1-/- tumor cells (ST, PNF) express higher levels of 
classical hormone receptors tested than either NF1+/- (SKOSC) or NF1+/+ (D3SC, 
SW10) cells, suggesting that NF1-/- cells would be more likely to respond to steroid 
hormones. Estrogen receptor (ER), androgen receptor (AR), and progesterone receptor 
(PR) were all expressed in highest levels in NF1-/- cells, while expression was greatly 
reduced/null in NF1+/- and NF1+/+ cells. Although PR expression was highest in NF1-/- 
cells, overall expression was lower than ER and AR (Roth et al., 2007b).  
 When we examined the effect that steroid hormone addition had on cell 
proliferation, we found a modest but significant increase in cell proliferation in DKOSC 
(NF1-/-) and ST88-14 (malignant NF1-/-) cells with all the hormones tested. Estrogen 
(E2) is the ER ligand, testosterone (T) is the AR ligand, and progesterone (P4) is the PR 
ligand, although they can rarely cross-react with the other receptors to a much lesser 
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extent than that with which they bind to their classical receptor. These modest 
proliferation increases were mainly returned to normal levels with the addition of 
classical hormone receptor inhibitors (ICI 182, 780 for ER, Flutamide for AR, and 
RU486 for PR), suggesting that this effect was at least partially mediated through 
classical hormone pathways. In some cases, however, increases were not returned to 
normal levels, suggesting other, non-classical pathway involvement (Roth et al., 2007b).  
Future studies will focus on the effects of these hormones separately and in 
combination, on these stem cell-derived cell lines and other cells whose NF1 status is 
known, including other malignant NF1 tumor cell lines in vitro and in vivo. We would 
like to see if there are effects such as downregulation, on NF1 expression in the presence 
of steroid hormones and/or inhibitors. Because of the complex hormonal milieu during 
pregnancy (Witorsch, 2002; Fernandez-Valdivia et al., 2005; Okada et al., 2005; 
Rodriguez-Cuenca et al., 2006), it will be necessary to look for synergy among hormone 
effects. Tumor growth response to steroid hormones may also be due to the effects on 
other NF1+/- cells in the tumor microenvironment, which may need to be studied in vivo 
in order to determine the many interactions that influence the effect of hormones on 
mouse tissues and hormone receptors. NF1 silencing and re-expression studies would be 
difficult due to the large transcript size of the NF1 gene (Friedman et al., 1999). 
 We will also investigate the mechanisms of these steroid hormones’ effects 
through mechanisms other than their classical nuclear receptors (figure 1.6). These 
include steroid hormone receptors localized to the plasma membrane and cytoplasm, 
including G protein-coupled receptors, c-src, and shc, which lead to MAPK and P13K 
signaling cascades activation (Honda et al., 2000; Pietras et al., 2001; Razandi et al., 
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2002; Levin, 2005; Levin and Pietras, 2007; Pedram et al., 2007). There have also been 
reports of novel G protein-coupled receptors unrelated to the classical nuclear steroid 
hormone receptors that can mediate rapid non-genomic effects of steroid hormones 
through adenylyl cyclase inhibition and cAMP production that activates the MAPK 
pathway (Levin, 2001; Pedram et al., 2002; Revankar et al., 2005; Boonyaratanakornkit 
and Edwards, 2007). Non-classical effects of E2 have been better characterized than 
those of T and P4, including through possible mitochondrial non-genomic membrane-
bound E2 receptors (Chen et al., 2005; Gavrilova-Jordan and Price, 2007). ER, as well as 
AR and PR, have been found in both the plasma membrane as well as the cell cytoplasm 
(Razandi et al., 2002; Levin, 2005; Levin and Pietras, 2007; Pedram et al., 2007).  
 In this dissertation, we also hypothesized that the complex hormonal milieu 
during pregnancy (Grow, 2002; Fishbein et al., 2007) or the response to these hormones 
may be different in women with NF1.  For example, 2-methoxy-estradiol (2ME2), which 
is an estrogen metabolite, has been found to be upregulated during pregnancy (Wang et 
al., 2000), but may either be present in lower levels systemically in women with NF1, 
resulting in tumor overgrowth, or cell receptors for 2ME2 may be lacking in NF1-/- cells. 
2ME2 has been found to be cytotoxic to numerous tumor cells as well as some other 
rapidly-growing cells (Mabjeesh et al., 2003), but not to normal or quiescent cells, by 
inducing apoptosis (Wang et al., 2000; Ireson et al., 2004). 2ME2 has no E2-like activity 
and has very low affinity for the ER; its effects are not classical ER-dependent (Wang et 
al., 2000; Ireson et al., 2004). In a study using prostate cancer cells grown in culture, it 
was found that the effect of 2ME2 was to block cell-cycle progression at the G2/M stage 
(Kumar et al., 2001). The mechanism of 2ME2 action in cultured cells is reported to be 
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through dissociation of microtubules (Mabjeesh et al., 2003). Neurofibromin has been 
found to associate and co-purify with microtubules, suggesting NF1 involvement in 
microtubule-mediated pathways (Gregory et al., 1993). It would therefore be interesting 
to see whether 2ME2 addition would change NF1 expression patterns, since the effect of 
2ME2 is to disaggregate microtubules, and other anti-mitotic drugs (e.g. colcemid) have 
been found to disaggregate neurofibromin staining, which recovered after drug removal 
(Gregory et al., 1993). We found that 2ME2, a naturally occurring estrogen metabolite, 
disrupted microtubules and was cytotoxic to malignant NF1 tumor cells while its effect 
was to slow or halt the growth of the other cells lines tested, regardless of their NF1 
status. This suggests that perhaps additional mutations, for example p53, which has been 
associated with MPNSTs (Menon et al., 1990), are needed for 2ME2 cytotoxic effects 
specific to malignant tumors, since non-malignant NF1 tumor cells did not undergo 
apoptosis with 2ME2 treatment.  
 Neurofibromas tend to be highly vascular (Thomas and De Vries, 2007). 
Therefore, we also hypothesize that the effect of hormones on neurofibromas may be 
indirect through hormonal effect on angiogenesis (Ruohola et al., 1999; Roth et al., 
2007a), due to the heterogeneous effect of hormones on SC-like and NF1 tumor cells. 
Mast cells, which are found in neurofibromas as well as various other tumors such as 
mammary carcinomas and melanomas, express factors which could be tumor-beneficial 
(Theoharis and Conti, 2004; Marone et al., 2002). Some of these factors function to 
induce neovascularization, such as heparin, interleukin-8 (IL-8) and vascular endothelial 
growth factor (VEGF) (Theoharis and Conti, 2004; Marone et al., 2002). Mast cells 
accumulate at sites of tumors in response to chemoattractants implicated in tumor growth, 
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such as Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES) 
and Monocyte chemotactic protein-1 (MCP-1) (Theoharis and Conti, 2004). It is of 
interest to note that we have found increased MCP-1 mRNA expression in NF1-/- 
(DKOSC) SC-like cells using RTqPCR (not shown). Increased blood vessel formation 
during pregnancy, initiated by mast cell accumulation, could allow existing tumors to 
grow as well as increase microscopic tumors to grow to detectable sizes.  
 It is also worth noting that while most of the cultures used in these studies are 
mouse cells, the tumor cell cultures are from human neurofibromas, which may explain 
some of the disparate results. With conditional mouse NF1 knockout models, we are 
getting closer to being able to recapitulate the human NF1 condition using mouse 
systems. 
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SYNTHESIZED ESTROGEN HORMONE METABOLITES HAVE 
HETEROGENEOUS EFFECTS ON CELL PROLIFERATION    
 Following the discovery that the naturally occurring estrogen metabolite 2ME2 
was cytotoxic only to malignant NF1-/- ST88-14 MPNST tumor cells, we sought to find 
another estrogen derivative that could be effective at inducing apoptosis in tumor cells at 
lower concentrations. Twelve estrogen metabolites were synthesized by Dr. Douglas 
Jewett in our lab and assayed for anti-proliferative or cytotoxic effects on hormone 
receptor-positive tumor cell lines (table A.1). The effect of these compounds was not 
consistent-none tested was cytotoxic to all tested cell lines. This is most likely because 
the cell lines expressed a variety of different hormone receptors. Regarding the malignant 
NF1-/- ST88-14 MPNST tumor cells, both 2MeO2bisMATE and 2ME2disulfamate in 
addition to 2ME2 were cytotoxic at 10µM (table A.1). A follow-up assay suggested that 
2MeO2bisMATE, but not 2ME2 or 2ME2disulfamate, was cytotoxic to malignant (ST88-
14) NF1-/- tumor cells at 1µM, one-tenth the concentration needed for cytotoxicity 
(figure A.1, 2ME2disulfamate not shown). A benign (pNF00.11) NF1-/- tumor cell line 
and a mouse NF1+ SC line (SW10) reduced/halted proliferation in response to either 
2ME2 or 2MeO2bisMATE (figure A.1). Additional estrogen compounds tested had 
limited/no effect on cell proliferation even at 10µM (table A.1, figure A.2).  
 Further assays were then performed to compare the effects of 2ME2bisMATE to 
2ME2 on cell proliferation and cytotoxicity in the malignant NF1-/- ST88-14 MPNST 
tumor cells and NF1+/+, NF1+/- or NF1-/- SC-like cells. We found that the number of 
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proliferating cells decreased in all cell lines tested after 2 says’ exposure to either 2ME2 
or 2MeO2bisMATE (figure A.3), however, only malignant NF1-/- ST88-14 MPNST 
tumor cells showed significant apoptosis at 1µM 2MeO2bisMATE (figure A.4). This data 
suggests that therapeutic compounds specifically cytotoxic at low concentrations to 
malignant tumor cells could possibly be synthesized.      
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Figure A.1: Cytotoxic effects of synthesized estrogen metabolites. Application of 
2MeO2bisMATE (1.0 µM) is cytotoxic to NF1-/- malignant peripheral nerve sheath 
(MPNST) (ST) cells at one-tenth the concentration of 2ME2 (10 µM) .A: Decreased 
numbers of metabolizing cells from the original number was seen only in a malignant 
NF1-/- cell line tested, while a benign human plexiform neurofibroma (PNF) cell line and 
a mouse NF1+ SC line (SW10) only showed decreased proliferation. B: 2MeO2-
bisMATE (1.0 µM) showed this effect using one-tenth the concentration of 2ME2 (10 
µM).  
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Figure A.2: Not all synthesized estrogen metabolites affected cell proliferation. For 
example, E2 bis sulfamate showed no effect on cell proliferation after 2 days’ application 
of up to 10 µM. 
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Figure A.3: SC-like and malignant peripheral nerve sheath tumor (MPNST) cells grown 
in the presence of 2ME2 or 2MeO2bisMATE decrease proliferation. Application of  1.0 
µM 2MeO2bisMATE to all cells, regardless of NF1 status, showed a decrease in 
proliferation over two days at, one-tenth the concentration of 2ME that decreased cell 
proliferation at 10 µM. Cell types tested inlcuded the SC-like A. D3SC (NF1+/+), B. 
SKOSC (NF1+/-), C. DKOSC (NF1-/-) and D. MPNST (ST) cells. Decreased cell 
proliferation could be the result of cytotoxicity or cell cycle arrest. 40x magnification.
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Figure A.4: 2MeO2bisMATE causes apoptosis in malignant NF1-/- MPNST cells at one-
tenth the concentration of 2ME2. Decreased cell proliferation (see figure A.4) could be 
the result of apoptosis or cell quiescence. Two day application of 2MeO2bisMATE 
resulted in a considerable percentage of apoptotic cells only in MPNST (ST) cells at 1.0 
µM, one-tenth the concentration of 2ME that resulted in apoptotic ST cells at 10 µM. SC-
like cells A. D3SC (NF1+/+), B. SKOSC (NF1+/-), and C. DKOSC (NF1-/-) cells 
showed very little apoptosis (~1%), while MPNST cells D. ST (NF1-/-) cells showed a 
considerable percentage of apoptotic cells (~20%). 40x magnification.
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Table A.1: The effect of estrogen metabolites is not consistent across cancer cell lines. 
We tested a range of synthesized hormones at concentrations of either 0 µM or 10 µM on 
a variety of hormone receptor-positive cancer cells. Only 2ME2, 2MeO2-bisMATE and 
2ME2-disulfamate were cytotoxic at 10 µM to malignant NF1-/- ST cells. Only2MeO2-
bisMATE was cytotoxic at 1.0 µM (not shown). Synthesized hormone metabolites’ 
effects were heterogeneous among the hormone receptor-positive cell lines tested-none 
was cytotoxic to all cell types.
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 Effect of 10uM estrogen metabolites on various 
cancer cell lines' proliferation over 3 days 
cell line 
ST88-14 
(MPNST) 
N15C6 
AR+ 
(LNCaP) 
PR+ 
(MCF-7) 
ER+ 
(MCF-7) 
metabolite         
2ME2 D P L L 
2MeO2bisMATE D P L L 
2-OH E2 
Trisulfamate NE L L NE 
4-Sulfamyl 
Tamoxifen NE D D P 
E10 2500 
Trisulfamate L L L NE 
Resvemtrol 
Sulfamate L L NE S 
C 16 Disulfamate NE L NE NE 
2ME2 
Disulfamate D S S S 
4-OH Tamoxifen NE D D D 
E 2510 
Sulfamate P S P P 
Sulfamyl 
Raloxifene NE NE NE NE 
C 18 Disulfamate NE S NE NE 
NE=no effect, L=significantly less than control,                       
S=static numbers, P=Partial cell death (some cells 
undergo apoptosis), D=cell death 
 
